

# Genetics of Amyotrophic Lateral Sclerosis

Max Koppers<sup>1,2</sup>, Michael van Es<sup>1</sup>, Leonard H. van den Berg<sup>1</sup>,  
Jan H. Veldink<sup>1\*</sup> and R. Jeroen Pasterkamp<sup>1,2\*</sup>

<sup>1</sup>*Departments of Neurology, University Medical Center Utrecht,*

<sup>2</sup>*Department of Neuroscience and Pharmacology, University Medical Center Utrecht,  
The Netherlands*

## 1. Introduction

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscle weakness caused by loss of central and peripheral motor neurons. Symptoms typically have a localized limb or bulbar onset and progress to other muscle groups of the body. Denervation of respiratory muscles and dysphagia leading to respiratory complications are the most common causes of death. There is no cure for this rapidly progressive disease.

Approximately 5% of patients have a family history of ALS (fALS) (Byrne et al., 2011). All other cases are considered to have a sporadic form of the disease (sALS). A twin study of sALS patients has estimated heritability to be considerable (0.38-0.76), indicating an important genetic component in disease etiology (Al-Chalabi et al., 2010). sALS, therefore, is considered to be a disease of complex etiology with both genetic and environmental factors contributing to disease susceptibility.

This chapter will provide an overview of the current knowledge of the genetics of both fALS and sALS. There will be, however, particular emphasis on two sALS associated regions identified in a large genome wide association study namely, chromosomal region 9p21.2 and 19p13.11. Evidence for the association with these regions as well as the function of the relevant genes in these regions will be discussed.

## 2. Genetics of familial amyotrophic lateral sclerosis

Familial ALS is a genetically heterogeneous group of diseases for which linkage has been found for over 13 different loci (Table 1). These loci account for approximately 25-30% of all fALS cases. In addition, variants in several other genes have been implicated in fALS but most of these data are still inconclusive. All currently known fALS loci and the genes involved will be briefly discussed in this section.

### 2.1 ALS1 (SOD1)

Linkage analysis in autosomal-dominant fALS pedigrees associated the copper-zinc superoxide dismutase (*SOD1*) gene on chromosome 21q to ALS. Several point mutations in

---

\*Corresponding authors

<i>Name of Disease</i>	<i>Locus</i>	<i>Gene</i>	<i>Protein</i>	<i>Inheritance</i>	<i>Clinical features</i>
<b>ALS1</b>	21q22	<i>SOD1</i>	Cu/Zn superoxide dismutase	AD/AR	Typical ALS
<b>ALS2</b>	2q33	<i>ALSin</i>	ALSin	AR	Juvenile onset, slowly progressive, predominantly upper motor neuron signs
<b>ALS3</b>	18q21	N.K.	-	AD	Typical ALS, disease onset in legs
<b>ALS4</b>	9q34	<i>SETX</i>	Senataxin	AD	Childhood/Adolescent onset, slowly progressive, no respiratory and bulbar involvement
<b>ALS5</b>	15q15-21	<i>SPG11</i>	Spatacsin	AR	Juvenile onset, slowly progressive
<b>ALS6</b>	16p11.2	<i>FUS</i>	Fused in sarcoma	AD/AR	Typical ALS
<b>ALS7</b>	20p13	N.K.	-	AD	Typical ALS
<b>ALS8</b>	20q13	<i>VAPB</i>	VAMP-associated protein B	AD	Typical ALS, SMA and atypical ALS
<b>ALS9</b>	14q11	<i>ANG</i>	Angiogenin	AD	Typical ALS, frontotemporal dementia, Parkinson's disease
<b>ALS10</b>	1q36	<i>TARDBP</i>	TAR-DNA binding protein	AD	Typical ALS
<b>ALS11</b>	6q21	<i>FIG4</i>	PI(3,5)P(2)5-phosphatase	AD	Adult onset, prominent corticospinal tract signs
<b>ALS12</b>	10p13	<i>OPTN</i>	Optineurin	AD/AR	Adult onset
<b>ALS14</b>	9p13-p12	<i>VCP</i>	Valosin-containing protein	AD	Adult onset with or without FTD
<b>ALS-FTD1</b>	9q21-22	N.K.	-	AD	ALS, FTD
<b>ALS-FTD2</b>	9p13.2-21.3	<i>C9ORF72</i>	Chromosome 9 open reading frame 72	AD	ALS, FTD
<b>ALS-FTDP</b>	17q21.1	<i>MAPT</i>	Microtubule-associated protein tau	AD	Adult onset with FTD
<b>ALS-X</b>	Xcen	N.K.	-	XD	Adult onset

AD = Autosomal dominant, AR = Autosomal recessive, XD = X-linked dominant, FTD = frontotemporal dementia, SMA = spinal muscular atrophy, N.K. = not known, FTDP = frontotemporal dementia with parkinsonism

Table 1. Classification of familial ALS.

*SOD1* that co-segregated with the disease were identified in several of these pedigrees (Rosen et al., 1993). To date, over 150 different mutations in *SOD1* have been identified (see <http://alsod.iop.kcl.ac.uk>). Mutations have been reported in ~20% of fALS patients and in 1-4% of sALS patients (Pasinelli and Brown, 2006; Valdmanis and Rouleau, 2008).

The *SOD1* protein is a cytoplasmic enzyme that converts superoxide radicals, a by-product of oxidative phosphorylation, to hydrogen peroxide and molecular oxygen. The exact mechanism by which *SOD1* mutations lead to ALS pathology is unknown although several toxic properties of mutant *SOD1* such as aberrant oxidative stress, protein instability, and mitochondrial damage have been proposed to be causative (reviewed in Pasinelli and Brown, 2006). Interestingly, the presence of mutant *SOD1* in non-neuronal cells contributes to pathogenesis and is needed for disease progression (Ilieva et al., 2009). *SOD1* mutations most likely result in a toxic gain of function pathology since *SOD1* knockout mice do not develop motor neuron degeneration whereas transgenic mice overexpressing mutant *SOD1* show motor neuron degeneration and ALS-like pathology (Gurney et al., 1994; Reaume et al., 1996).

## 2.2 ALS2 (ALSin)

ALS2 is an autosomal recessive form of juvenile ALS that was first reported in a large consanguineous Tunisian kindred and linkage analysis in this family associated locus 2q33-q35 to ALS (Hentati et al., 1994). This led to the discovery of causal mutations in the gene encoding ALSin (Hadano et al., 2001; Yang et al., 2001). Mutations in *ALSin* have been scarcely reported and do not appear to be a common cause of ALS.

ALSin is a Rab5 and Rac1 guanine exchange factor that acts as a regulator of endosomal/membrane trafficking. The protein is able to promote neurite outgrowth in neuronal cultures through activation of the small GTPase Rac1 (Otomo et al., 2003; Topp et al., 2004). Overexpression of ALSin protects cultured motor neuronal cells from mutant *SOD1* toxicity suggesting a neuroprotective role. Mutations in *ALSin* may induce a loss of this neuroprotective function (Kanekura et al., 2004). *ALSin* knockout mice do not develop overt motor neuron disease but degeneration of the corticospinal tract has been reported (Cai et al., 2008; Hadano et al., 2006).

## 2.3 ALS3 (18q21)

Linkage to chromosome 18q21 was identified in a large European family of which 20 members had autosomal-dominant ALS (Hand et al., 2002). This region contains 50 genes but the causal mutation at this locus remains to be identified.

## 2.4 ALS4 (SETX)

ALS4 is a rare, childhood- or adolescent-onset, autosomal dominant disease, which is also known as distal hereditary motor neuronopathy with pyramidal features. Linkage to chromosome 9q34 was found in a large family from the USA with 49 affected members (Chance et al., 1998). Sequencing of 19 genes in this locus revealed that missense mutations in the senataxin (*SETX*) gene were the cause of ALS4 in several families (Chen et al., 2004). Since then, mutations have been identified in additional ALS patients from China, Italy and the USA (Avemaria et al., 2011; Hirano et al., 2011; Zhao et al., 2009). Interestingly, mutations in *SETX* leading to a premature termination in the protein product have also been identified in ataxia oculomotor apraxia 2 (Moreira et al., 2004).

Senataxin contains a seven-motif domain characteristic for DNA/RNA helicases. It displays strong homology to several genes involved in RNA processing such as the immunoglobulin mu binding protein 2 gene (*IGHMBP2*), in which mutations are known to cause spinal muscular atrophy with respiratory distress type 1 (Grohmann et al., 2001). *SETX* was shown to be involved in the termination of RNA transcription (Skourti-Stathaki et al., 2011). It is therefore possible that mutations in *SETX* cause neuronal degeneration due to aberrant RNA processing. Overexpression of wild-type senataxin in primary hippocampal neurons is sufficient to trigger neuronal differentiation by protecting cells from apoptosis and promoting neuritogenesis (Vantaggiato et al., 2011).

### 2.5 ALS5 (SPG11)

This is the most common form of recessive fALS and is characterized by a juvenile onset. In seven families from Tunisia, Pakistan, and Germany, linkage to chromosome 15q15-21 was found (Hentati et al., 1998). Recently, 12 mutations in the spatacsin (*SPG11*) gene were identified in 10 unrelated pedigrees from Italy, Brazil, Canada, Turkey, and Japan (Orlacchio et al., 2010). Ten out of 12 mutations are frameshift or nonsense mutations. Mutations in *SPG11* are known to cause autosomal recessive hereditary spastic paraplegia with a thin corpus callosum (Stevanin et al., 2007).

Spatacsin contains four putative transmembrane domains, a leucine zipper and a coiled-coil domain. The exact function of spatacsin is unknown although it may play a role in axonal transport (Salinas et al., 2008).

### 2.6 ALS6 (FUS)

Linkage to a 42-Mb region containing more than 400 genes on chromosome 16 was reported in several families (Sapp et al. 2003). Recently, mutations in the fused in sarcoma/translated in liposarcoma (*FUS/TLS*) gene were shown to cause ALS6 (Kwiatkowski et al., 2009; Vance et al., 2009). Several subsequent studies have identified additional mutations in *FUS* in ALS cohorts from different populations with an overall frequency of ~4% in fALS and ~1% in sALS (Belzil et al., 2009; Corrado et al., 2010; Hewitt et al., 2010; Groen et al., 2010). *FUS* mutations have also been detected in fALS patients with frontotemporal dementia (FTD) and patients with juvenile ALS with basophilic inclusions (Bäumer et al., 2010; Huang et al. 2010; Yan et al., 2010).

The *FUS* gene encodes for a DNA/RNA binding protein that is involved in several cellular pathways including the splicing, transport and maturation of RNA (Lagier-Tourenne et al., 2010). *FUS* positive ubiquitinated cytoplasmic inclusions have been observed in spinal cord tissue of sALS and fALS patients without *SOD1* and *FUS* mutations (Deng et al., 2010). The majority of *FUS* mutations identified reside in its C-terminal nuclear localization signal which results in an abnormal cytoplasmic localization of *FUS* and localization to stress granules (Bosco et al., 2010; Dormann et al., 2010; Ito et al., 2010). In yeast, overexpression of human *FUS* leads to toxicity, cytoplasmic inclusions and *FUS* localization to stress granules as can be seen in ALS patients (Ju et al., 2011; Sun et al., 2011). In addition, transgenic rats overexpressing ALS mutant *FUS* develop progressive paralysis due to motor axon degeneration as well as neuronal loss in the cortex and hippocampus which are phenotypes seen in ALS and FTD (Huang et al., 2011).

### 2.7 ALS7 (20p)

Linkage to chromosome 20p was found in a large autosomal dominant fALS pedigree from the USA. A 5-Mb segment was identified that was shared between two affected

siblings (Sapp et al., 2003). This region contains 24 genes but no causal mutation has been identified.

### 2.8 ALS8 (VAPB)

In a large family from Brazil with 28 affected members across 4 generations, linkage was found at chromosome 20q13.3. Sequencing identified a mutation (P56S) in the vesicle associated membrane protein (VAMP)/synaptobrevin-associated membrane protein B (*VAPB*) gene in all affected members of this family (Nishimura et al., 2004). The same mutation was also identified in six additional families with different clinical courses including, ALS8, late-onset spinal muscular atrophy and typical severe ALS with rapid progression. A different mutation (T46I) was detected in a family from the UK (Chen et al., 2010).

The VAPB protein has been implicated in various cellular processes including the formation of the presynaptic terminal in neurons, vesicle trafficking and the unfolded protein response (Chen et al., 2010). Transgenic mice overexpressing ALS mutant VAPB or wild-type VAPB do not develop an overt motor neuron phenotype. However, transgenic mice overexpressing ALS mutant but not wild-type VAPB show TAR DNA-binding protein 43 (TDP-43) positive cytoplasmic inclusions, a pathological hallmark of ALS (Tudor et al., 2010). It has been suggested that mutant VAPB exerts a dominant-negative effect by forming dimeric complexes with wild-type VAPB thereby recruiting it into aggregates (Teuling et al., 2007).

### 2.9 ALS9 (ANG)

Angiogenin (*ANG*) was identified as a candidate gene for ALS because it is located 237kb downstream of apurinic endonuclease, multifunctional DNA repair enzyme (*APEX*) and because of its functional similarity to vascular endothelial growth factor (*VEGF*) (Greenway et al., 2004). Both *APEX* and *VEGF* are candidate genes for sALS and will be discussed in the next section. A single nucleotide polymorphism (SNP) in *ANG* was associated with ALS in patients from Ireland and Scotland (Greenway et al., 2004). Missense mutations in *ANG* were found in 4 fALS cases and 11 sALS cases (Greenway et al., 2006). Subsequent sequencing in populations from Europe and the USA identified additional mutations in approximately 2% of fALS cases and 1% of sALS cases (Conforti et al., 2008; Fernández-Santiago et al., 2009; Gellera et al., 2008; Paubel et al., 2008; Wu et al., 2007). However, *ANG* mutations have also been observed in healthy controls suggesting that not all mutations are pathogenic (Corrado et al., 2007). A K17I mutation was identified in a 4-generation family of which one patient presented with ALS, FTD, and Parkinsonism (Van Es et al., 2009a). An obligate carrier did not develop the disease suggesting incomplete penetrance. Two *ANG* mutations (K17I and K54E) were identified in two fALS cases from France who also had a mutation in *FUS* (Millecamps et al., 2010). An R145C mutation has been observed in a sALS patient with a G93D *SOD1* mutation (Luigetti et al., 2011). A recent study showed a significantly higher frequency of *ANG* variants in both ALS and Parkinson's disease (PD) patients which could reflect a genetic susceptibility to widespread neurodegeneration (Van Es et al., 2011).

The *ANG* protein is a member of the pancreatic ribonuclease superfamily and a potent mediator of new blood vessel formation. In endothelial cells, the protein can promote ribosomal RNA (rRNA) production and cellular proliferation and is able to cleave transfer

RNA which results in inhibition of protein translation (Yamasaki et al., 2009). ANG is also expressed in spinal motor neurons (Sebastià et al., 2009). It is thought that ANG mutations cause ALS due to a loss of function and it has been shown that wild-type but not mutant angiogenin is neuroprotective and that mutant angiogenin impairs neurite outgrowth *in vitro* (Sebastià et al., 2009; Subramanian et al., 2008; Wu et al., 2007).

### 2.10 ALS10 (TARDBP)

TDP-43 was identified as one of the main components of ubiquitinated cytoplasmic inclusions in ALS and FTD (Neumann et al., 2006). Sequencing of the gene encoding this protein (*TARDBP*) identified mutations in ALS patients (Kabashi et al., 2008; Shreedharan et al., 2008). To date over 40 mutations in *TARDBP* have been identified in several different populations with a frequency of ~5% of fALS cases and up to 2% of sALS cases (Corrado et al., 2009; Iida et al., 2010; Millecamps et al., 2010; Ticozzi et al., 2009; Van Deerlin et al., 2008). *TARDBP* mutations have also been observed in ALS-FTD and FTD patients (Benajiba et al., 2009; Gitcho et al., 2009b). Despite the presence of *TARDBP* mutations in only a portion of ALS and FTD patients, TDP-43-positive cytoplasmic inclusions are found in almost all ALS patients but they are also seen in other neurodegenerative diseases such as FTD, Huntington's, Alzheimer's, and Parkinson's disease (Da Cruz and Cleveland, 2011).

TDP-43, like FUS, is a DNA/RNA binding protein that is part of the heterogeneous ribonucleoprotein family. It has a role in gene transcription, regulation of splicing, and mRNA transport and stabilization (Buratti and Baralle, 2010). Except for one truncation mutation, all *TARDBP* mutations identified in ALS patients are missense mutations clustered in the glycine-rich C-terminal region which is involved in protein-protein interactions (Lagier-Tourenne et al., 2010). *TARDBP* mutations lead to an abnormal distribution of the protein to the cytoplasm.

### 2.11 ALS11 (FIG4)

Mutations in the PI(3,5)P(2)5-phosphatase (*FIG4*) gene on chromosome 6q21 are known to cause a severe form of Charcot-Marie-Tooth (CMT) disease with early onset and loss of sensory and motor neurons, CMT4J (Chow et al., 2007). In a screen for *FIG4* mutations in a large cohort of sALS and fALS patients, several variants were detected that were unique to fALS and sALS patients (Chow et al., 2009). Two mutations were identified in patients diagnosed with primary lateral sclerosis. To date, no other studies have replicated the finding of ALS-associated *FIG4* mutations in other cohorts and it is unclear whether *FIG4* mutations are pathogenic in ALS patients.

*FIG4* is a phosphoinositide 5-phosphatase that regulates PI(3,5)P2 abundance. PI(3,5)P2 is a signalling lipid that mediates endosomal trafficking to the trans-Golgi network (Rutherford et al., 2006). Pale tremor mice, which are homozygous for null mutations in *FIG4*, show neurodegeneration in sensory and autonomic ganglia, motor cortex, striatum, and cerebellum. Motor neurons in the ventral spinal cord contain vacuoles (Chow et al., 2007). Mutant mice lacking *Vac14*, a gene encoding for a *FIG4* interactor, show a similar neurodegeneration (Zhang et al., 2007).

### 2.12 ALS12 (OPTN)

Using homozygosity mapping in six ALS patients from consanguineous marriages, an overlapping region on chromosome 10 was identified as the candidate region. Screening of

17 genes in this region revealed a homozygous deletion in the gene for optineurin (*OPTN*), a gene known to cause primary open-angle glaucoma, in two siblings and an individual from a different family (Murayama et al., 2010; Rezaie et al., 2002). In addition, a homozygous nonsense (Q398X) mutation was identified in one fALS case (Murayama et al., 2010). Subsequent screening in a larger cohort of fALS and sALS patients identified a heterozygous missense mutation (E478G) in a four individuals with ALS from two families (Murayama et al., 2010). A homozygous E478G mutation was identified in a Japanese fALS case in a different study (Iida et al., 2011). One additional nonsense mutation and one missense mutation in *OPTN* were identified in fALS cases from Italy (Del Bo et al., 2011). Two separate studies identified novel variants in fALS patients but the authors state that these variants may be a genetic predisposition to glaucoma instead of causing ALS (Belzil et al., 2011; Millecamps et al., 2011). One study also detected mutations in sALS patients with a rapid disease progression (van Blitterswijk et al., 2011). Another study could not identify *OPTN* mutations in fALS and sALS patients (Sugihara et al., 2011).

*OPTN* is a multifunctional protein involved in membrane trafficking, maintenance of the Golgi complex, and exocytosis (Sahlender et al., 2005). *OPTN* can inhibit the activation of NF $\kappa$ B and it has been proposed that mutations in *OPTN* causing ALS may relieve this inhibition and cause neuronal death (Murayama et al., 2010).

### 2.13 ALS14 (VCP)

Recently an exome sequencing study detected a mutation in the gene encoding valosin-containing protein (*VCP*) in an Italian family. Subsequent screening in 210 ALS cases from unrelated families identified four mutations in *VCP* in four different families from Italy and the USA (Johnson et al., 2010). Mutations in the gene for *VCP*, located on chromosome 9p13.3, are a known cause for the multi-system degenerative disease inclusion body myopathy with Paget's disease and frontotemporal dementia (IBMPFD) (Watts et al. 2004). IBMPFD, like ALS, is characterized pathologically by TDP-43 inclusions (Weihl et al., 2008). *VCP* is an AAA+-ATPase that mediates ubiquitin-dependent extraction of substrates from multiprotein complexes for subsequent recycling or degradation by the proteasome. It plays a role in a variety of cellular functions including Golgi biogenesis, cell cycle regulation, DNA damage repair and protein homeostasis through the ubiquitin-proteasome system (Ju and Weihl, 2010). It is thought that *VCP* mutations result in the impairment of protein degradation through both the ubiquitin-proteasome system and autophagy leading to the formation of inclusions. *VCP* mutations found in FTLD and ALS have been shown to disrupt TDP-43 localization from the nucleus to the cytoplasm which could be caused by the disruption in protein homeostasis (Gitcho et al, 2009a; Ju and Weihl, 2010). In mice, a missense mutation in vacuolar sorting protein 54, the mouse homologue of *VCP*, causes motor neuron degeneration (Schmitt-John et al., 2005).

### 2.14 Other fALS associated genes

In addition to the genes listed in the previous sections, several other genes have been implicated in fALS.

Dynactin 1 (*DCTN1*) was discovered as a candidate gene for ALS when a G59S mutation in this gene was identified in a family with a slowly progressive, autosomal dominant form of lower motor neuron disease without sensory symptoms (Puls et al., 2003; Puls et al., 2005). Subsequent sequencing of the *DCNT1* gene in 250 ALS patients revealed the presence of

three heterozygous missense mutations in one sALS and three fALS cases with typical ALS (Münch et al., 2004). An additional mutation was detected in a patient with ALS and his brother who had FTD (Münch et al., 2005). The pathogenicity of these variants has however not been established. Screening for *DCTN1* mutations in a cohort of ALS, FTD or ALS-FTD patients did not result in the identification of disease segregating variants (Vilariño-Güell et al., 2009). One of the missense variants identified in a sALS case was also found in controls in the same study (Vilariño-Güell et al., 2009). Interestingly, five mutations in *DCTN1* were found in eight families with Perry syndrome, a disease that is characterized by Parkinsonism and TDP-43- and ubiquitin- positive inclusions (Farrer et al., 2009).

In a 3-generation family with typical ALS, a mutation in the D-amino acid oxidase (*DAO*) gene was identified (Mitchell et al., 2010). However, screening of an additional 322 unrelated fALS cases did not reveal any other causal mutation in this gene (Mitchell et al., 2010). Additional screening will be needed but *DAO* mutations seem to be very rare in ALS. Because of their structural and functional similarities to FUS, the genes encoding TAF15 RNA polymerase II, TATA box binding protein associated factor (*TAF15*) and Ewing sarcoma breakpoint region 1 (*EWS*) were screened in fALS cases (Ticozzi et al., 2010). Two missense mutations in *TAF15* (A31T and R395Q) were identified in three fALS cases and not in 1159 controls. However, one of the fALS cases with an R395Q mutation also carried a mutation in *TARDBP*. Moreover, the R395Q is in close proximity to two non-pathogenic variants, suggesting it is a benign polymorphism (Ticozzi et al., 2010).

Recently, a mutation in the sigma non-opioid intracellular receptor 1 (*SIGMAR1*) gene was identified in an autosomal recessive family with juvenile ALS (Al-Saif et al., 2011). Interestingly, variants in the 3'UTR of *SIGMAR1* were described in three ALS-FTD families (Luty et al., 2010).

An X-linked dominant ALS locus has been reported but has not been further described (Siddique et al., 1998). Recently, mutations in the gene encoding ubiquitin-like protein ubiquilin 2 (*UBQLN2*) were identified as the cause of dominantly inherited X-linked ALS and ALS/dementia (Deng et al., 2011).

Several family pedigrees contain individuals affected by ALS, FTD or both. The first linkage study performed in 16 of these ALS-FTD families found linkage to chromosome **9q21-q22**, designated as ALS-FTD1 (Hosler et al., 2000). This association has thus far not been replicated in other ALS-FTD families. Linkage to chromosome 9p in ALS-FTD families (ALS-FTD2) has also been reported. A hexanucleotide repeat expansion in the chromosome 9 open reading frame 72 (*C9ORF72*) gene was recently identified as the causal genetic defect of ALS-FTD2 and will be discussed in a next section (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Mutations in the gene encoding microtubule-associated protein tau (*MAPT*) have been reported in patients with ALS or FTD (Hutton et al., 1998).

Finally, mutations in the neurofilament heavy (*NEFH*) gene and the paraoxonase genes (*PON1*, 2, 3) have been identified in fALS cases and these genes will be discussed in more detail in the following section.

### 3. Genetics of sporadic ALS

Sporadic ALS is considered to be a complex disease, where both genetic and environmental factors contribute to pathogenesis. Several association studies have been performed to identify the genetic contribution in sALS with mixed success, possibly due to the small sample sizes in many of these studies. Although their precise contribution to sALS is often unclear, a few of



the risk factors identified to date have been consistently replicated. Furthermore, several of these associated genes have overlapping cellular functions such as in RNA metabolism, vesicle trafficking, and axonal transport. In this section, genes that have been associated with sALS will be discussed (Table 2). In addition to these genes, mutations in several fALS associated genes that were discussed in the previous section have been found in a portion of sALS cases.

<i>Associated Gene</i>	<i>Protein</i>	<i>Positive studies</i>	<i>Negative studies</i>	<i>Type of association found</i>	<i>Additional information</i>
<i>APEX</i>	Apurinic endonuclease, DNA repair enzyme	2	2	SNP association	Protein has a role in oxidative stress
<i>ATXN2</i>	Ataxin-2	6	0	PolyQ repeats	Intermediate polyQ repeats increase risk for sALS/interaction with TDP-43
<i>CHMP2B</i>	Chromatin modifying protein 2B	2	0	Mutations	Mutations are known to cause FTD. All patients have lower motor neuron signs consistent with PMA.
<i>HFE</i>	Haemochromatosis	5	1	SNP association	Mutations cause hereditary haemochromatosis
<i>NEFH</i>	Neurofilament-heavy	5	3	Deletions/ insertions/ mutations	Neurofilament-containing inclusions are a pathological hallmark of ALS
<i>SMN1</i>	Survival motor neuron 1	3	1	Abnormal copy number	<i>SMN1</i> deletions cause SMA
<i>SMN2</i>	Survival motor neuron 2	1	5	Deletions	<i>SMN2</i> copy number variation affects SMA disease severity
<i>PON1, 2, 3</i>	Paraoxonase	7	3	SNP association/ mutations	Possible gene-environment interaction
<i>PRPH</i>	Peripherin	3	0	Mutations	Peripherin-containing inclusions are a pathological hallmark of ALS. Possible involvement of abnormal splice forms.
<i>VEGF</i>	Vascular-endothelial growth factor	2	6	SNP association	Deletion of HRE in promoter results in an ALS phenotype in mice. Possible gender association.

Table 2. Genes associated with sporadic ALS

### 3.1 Apurinic endonuclease, multifunctional DNA repair enzyme (*APEX1*)

A study in 117 Scottish sALS patients showed association of a common SNP resulting in a D148E amino-acid change with ALS (Hayward et al., 1999). This finding was replicated in 169 Irish sALS patients (Greenway et al., 2004). In one study, DNA extracted from CNS tissue from 81 sALS patients was screened but the D184E SNP was not associated with ALS (Tomkins et al., 2000). A different study assessing 134 Italian sALS patients also failed to detect significant association between this SNP and ALS (Coppedè et al., 2010). These inconsistent association results might reflect a population-specific effect of the *APEX1* D184E allele.

APEX1 is involved in DNA repair and maintains and stimulates the DNA binding activity of transcription factors (Fishel and Kelley, 2007). Frontal cortical levels and activity of APEX1 were significantly reduced in 11 ALS patients as compared to six controls (Kisby et al., 1997). However, in a different study, increased expression levels and activity in ALS brain and spinal cord motor neurons were observed (Shaikh and Martin, 2002).

### 3.2 Ataxin-2 (ATXN2)

In a screen for toxicity modifiers of TDP-43 in yeast, ataxin-2 (ATXN2) was identified (Elden et al., 2010). ATXN2 and TDP-43 form a RNA-dependent complex and are mislocalized in spinal cord motor neurons in ALS patients. ATXN2 has a polyglutamine (polyQ) region which is normally 22-23 repeats long. Expansion of this region of the protein to 34 repeats causes spinocerebellar ataxia type 2 (SCA2) (Imbert et al., 1996; Pulst et al., 1996; Sanpei et al. 1996). The polyQ repeat length of ATXN2 was determined in 915 ALS patients and 980 controls and intermediate length polyQ repeats (23-34) were found to be more common in ALS patients and thus may be a risk factor for ALS (Elden et al., 2010). This finding was replicated in several studies with ALS patients from different populations. Interestingly, the exact length of the polyQ repeat region seems to vary between populations (Chen et al., 2011; Daoud et al., 2011; Lee et al., 2011; Ross et al., 2011; Van Damme et al., 2011).

Longer polyQ repeats in ATXN2 possibly stabilize the protein and enhance its interaction with TDP-43. Under stress conditions, increased mislocalization of TDP-43 to the cytoplasm was observed in cells harbouring expanded polyQ repeats in ATXN2 (Elden et al., 2010). ATXN2 was shown to be part of stress granules and interacts with poly-A-binding-protein 1 (PABP), which is involved in poly(A) shortening and translation initiation (Ralsler et al., 2005). ATXN2 was also shown to interact with endophilin A1 and A3, which are involved in synaptic vesicle endocytosis (Nonis et al., 2008).

### 3.3 Chromatin modifying protein 2B (CHMP2B)

A mutation in a splice-site of *CHMP2B* was first identified in a large Danish family with FTD and mutations have since been detected at low frequency in other FTD patients (Skibinski et al., 2005). Screening of the *CHMP2B* gene in ALS patients identified two mutations in two fALS patients. These patients displayed a predominant lower motor neuron phenotype and one of the patients showed signs of FTD (Parkinson et al., 2006). Sequencing of the *CHMP2B* gene in 433 ALS patients identified three missense mutations in one fALS case and three sALS cases (Cox et al., 2010).

The exact function of CHMP2B is unknown but its yeast homologue, vacuolar protein sorting 2 (VPS2), is a component of the ESCRTIII complex (Skibinski et al., 2005). This complex is involved in the trafficking of proteins between plasma membrane, trans-Golgi network, and lysosomes. The *CHMP2B* mutation identified in FTD results in dysmorphic endosomal structures similar to what is seen in ALSin overexpression (Skibinski et al., 2005). In cortical neurons, overexpression of the FTD related CHMP2B splice-site mutant leads to dendritic retraction prior to cell death and the accumulation of autophagosomes (Lee et al., 2007). In hippocampal neurons, the same FTD related CHMP2B mutant causes a decrease in large dendritic spines suggesting that CHMP2B is needed for dendritic spine growth and maturation (Belly et al., 2010).

### 3.4 Haemochromatosis (HFE)

Mutations in the *HFE* gene are a cause of hereditary haemochromatosis and have been associated with Alzheimer's disease and PD (reviewed by Nandar and Connor, 2011). The first report examining the presence of *HFE* mutations in ALS found no association between two mutations (H63D and C282Y) and ALS patients from the USA (Yen et al., 2004). However, several subsequent studies in a total of 1133 ALS patients and almost 7000 controls individuals from the USA, Ireland, UK, Italy, The Netherlands, and China reported association between the *HFE* H63D polymorphism and an increased risk for ALS (Goodall et al., 2005; He et al, 2011; Restagno et al., 2007; Sutedja et al., 2007; Wang et al., 2004).

The most important function of HFE is the regulation of iron homeostasis by binding to the transferrin receptor and reducing the transport of iron molecules (Feder et al., 1998). When HFE with the H63D mutation binds to the transferrin receptor, iron transport is reduced leading to iron accumulation and increased oxidative stress. In addition, it has been shown that in neuronal cell lines the H63D mutation induces increased oxidative stress, altered glutamate regulation and prolonged ER stress, all cellular processes affected in ALS (Liu et al., 2011; Mitchell et al. 2011).

### 3.5 Neurofilaments (NEFL, NEFM, NEFH)

One of the pathological hallmarks of ALS is the presence of neurofilament-containing inclusions in the cell body and proximal axon of spinal motor neurons (Delisle and Carpenter, 1984). Neurofilaments are intermediate filaments that constitute the most abundant cytoskeletal element in large myelinated axons. Neurofilaments are formed by the co-polymerization of light (NEFL), medium (NEFM), and heavy (NEFH) subunits, which are each encoded by different genes.

Several lines of evidence suggest a role for neurofilaments in neurodegeneration. Initial evidence came from mouse models overexpressing or deficient for neurofilaments (reviewed in Lariviere and Julien, 2004). Overexpression of NEFL or NEFH resulted in an abnormal accumulation of neurofilaments, as seen in ALS patients, and in axonal atrophy and motor dysfunction but not degeneration. Surprisingly, both overexpression and knockout of neurofilaments in transgenic mutant SOD1 mice increases life span (Couillard-Després et al., 1998; Williamson et al., 1998). This indicates that the role of neurofilaments in ALS is complex and more research is needed to examine the possible contribution of neurofilaments to ALS pathogenesis.

Additional evidence for a role for neurofilaments in ALS comes from genetic studies. Mutations in *NEFL* have been identified in some forms of the sensory and motor neuropathy Charcot-Marie-Tooth disease (Mersyanova et al., 2000; Shin et al., 2008). The C-terminal tail region of NEFH contains phosphorylation motifs known as KSP repeats. In humans there are two common polymorphic variants of 44 (short) or 45 (long) repeats. Homozygosity for the short repeat allele is associated with Russian sporadic motor neuron disease patients (Skvortsova et al., 2004). Deletions and insertions in the KSP repeats of *NEFH* were detected in ALS patients (Al-Chalabi et al., 1999; Figlewicz et al., 1994; Tomkins et al., 1998). However, another study in 117 unrelated fALS patients could not identify deletions or insertions in the KSP repeats of *NEFH* (Rooke et al., 1996). A missense mutation in the *NEFH* gene was identified in a sALS case and not in controls (Garcia et al., 2006). Moreover, in a recent candidate gene sequencing study, three missense mutations were identified in the *NEFH* gene in two sALS and one fALS case. However, co-segregation of the mutation in the

fALS case could not be tested and none of the missense mutations were predicted to be deleterious (Daoud et al., 2011). One study did not identify ALS specific variation in the *NEFH* gene in fALS and sALS samples (Vechio et al., 1996).

### 3.6 Paraoxonase genes (PON)

The paraoxonase gene cluster consists of 3 genes (*PON1*, *PON2*, and *PON3*) and is located in an 80-kb block on chromosome 7q21.3-22.1. *PON1* and *PON3* are primarily expressed in liver where they are associated with high-density lipoproteins, whereas *PON2* is ubiquitously expressed (Costa et al., 2005; Draganov et al., 2000; Ng et al., 2002). Both *PON1* and *PON2* expression has been shown in mouse brain (Giordano et al., 2011). All *PON* proteins are able to hydrolyze lactones and *PON1* is able to detoxify organophosphate pesticides and neurotoxins. Since neurotoxins are not normally present in the body the biological function of *PON1* is thought to be protection of low-density lipoproteins from oxidation (Mackness et al., 1991). *PON2* and *PON3* share this function (Draganov et al., 2000; Ng et al., 2001). A higher incidence of ALS among Gulf war veterans and farmers suggested that chemical exposure may be a risk factor for ALS (Chió et al., 1991; Horner et al., 2003). Because *PON* proteins reduce oxidation and are able to detoxify neurotoxins these proteins have been investigated for association with ALS.

Polymorphisms in *PON1* and *PON2* as well as a haploblock spanning *PON2* and *PON3* were found to be associated with sALS (Saeed et al., 2006; Slowik et al., 2006). Since then several other studies in different populations have reported association of SNPs in the *PON* genes with sALS (Cronin et al., 2007; Landers et al., 2008; Morahan et al., 2007; Valdmanis et al., 2008). However, a meta-analysis including 4037 cases and 4609 controls from five case-control studies and several genome-wide association studies showed no significant association between *PON* polymorphisms and ALS (Wills et al., 2009). More recently, two other studies failed to detect association between *PON* polymorphisms and ALS (Ricci et al., 2011; Zawislak et al., 2010). In a recent sequencing study, eight mutations in all three *PON* genes were identified in fALS and sALS patients (Ticozzi et al., 2010). Mutations in the *PON* genes might play a role in ALS but additional sequencing is needed to confirm this.

Interestingly, *PON1* activity can vary greatly depending on polymorphisms in its coding region (Costa et al., 2005). Thus, mutations in the *PON* genes could affect *PON* activity and thereby contribute to ALS pathogenesis. Toxicity in neurons caused by oxidative stress was higher in cells from *PON2* knockout mice than in wild-type mice, suggesting that *PON2* has a protective effect against neurotoxicity caused by oxidative stress (Giordano et al., 2011).

### 3.7 Peripherin (PRPH)

Peripherin is an intermediate filament similar to neurofilaments and is also associated with axonal spheroids in the proximal axon of spinal cord motor neurons of ALS patients (Corbo and Hays, 1992). It is also present in Lewy body-like inclusions and Bunina bodies that are seen in a portion of ALS patients (He and Hays, 2004; Mizuno et al., 2011). Peripherin is predominantly expressed in the peripheral nervous system and in spinal motor neurons in the central nervous system. After neuronal injury, peripherin expression is upregulated in spinal motor neurons and this upregulation has been linked to axonal regeneration (Troy et al., 1990). However, transgenic mice with wild-type overexpression of peripherin develop a late-onset and selective motor neuron disease characterized by intermediate filament inclusions (Beaulieu et al., 1999). For these reasons, the possibility of *PRPH* mutations in

ALS patients was investigated. Two missense mutations and a frameshift deletion in the *PRPH* gene have been identified in sALS patients (Corrado et al., 2011; Gros-Louis et al., 2004; Leung et al., 2004). Additional screening of the *PRPH* gene for mutations in larger cohorts of ALS patients and controls is needed to determine the frequency and pathogenicity of *PRPH* mutations.

Expression of abnormal peripherin splice variants has also been suggested to play a role in ALS pathogenesis. A toxic splice variant of peripherin (Per61) was found in motor neurons of mutant SOD1 transgenic mice but not wild-type mice (Robertson et al., 2003). Expression of Per61 has more recently also been observed in mutant TDP-43 transgenic mice but not in wild-type TDP-43 transgenic mice (Swarup et al., 2011). In addition, Per61 specific antibodies stain aggregates in human ALS but not in control spinal cord (Swarup et al., 2011). The presence of abnormal peripherin splice variants (Per28) has also been shown in humans (Xiao et al., 2008). Per28 overexpression results in peripherin aggregation and an upregulation of peripherin expression at the mRNA and protein levels in ALS patients as compared to controls (Xiao et al., 2008). A different study showed expression of Per28 in lumbar spinal cord lysates of ALS patients but not control cases (McLean et al., 2010). Although the functional significance of these abnormal splice forms is unknown they seem to play a role in the development ALS.

### 3.8 Survival motor neuron (SMN) 1 and 2

Two highly homologous copies of the survival motor neuron gene exist in humans, telomeric *SMN1* and centromeric *SMN2*. *SMN2*, which lacks exon 7 due to a nucleotide difference in a splice enhancer site, produces a less stable SMN protein and has only 20% of the biological function of *SMN1* (Lorson et al., 1998). It has been shown that TDP-43 overexpression regulates the inclusion of exon 7 during pre-mRNA splicing of *SMN2* (Bose et al., 2008).

Deletions or mutations in *SMN1* cause the autosomal recessive disorder spinal muscular atrophy (SMA), whereas variation in *SMN2* copy number affects SMA disease severity (Lefebvre et al., 1997). SMA patients with a higher copy number of *SMN2* generally have a milder form of the disease (Gavrilov et al., 1998). *SMN1* is widely expressed and functions in the assembly of the spliceosome as part of the SMN complex. *SMN1* also interacts with several proteins involved in mRNA editing, transport, splicing, transcriptional regulation, and post-transcriptional processing and modification of rRNA (Eggert et al., 2006). The impaired assembly of the spliceosome could lead to neuronal degeneration.

Thus far, five different studies have failed to detect homozygous *SMN1* deletions in ALS patients (Gamez et al., 2002; Jackson et al., 1996; Moulard et al., 1998; Orrell et al., 1997; Parboosingh et al., 1999). However, an increased frequency of abnormal copy number (one or three copies) of *SMN1* was found in ALS patients compared to controls (Corcia et al., 2002). However, these results were inconsistent with other reports (Corcia et al., 2006; Veldink et al., 2001; Veldink et al., 2005). Recently, a large study was published including new samples of 847 sALS patients and 984 controls, showing that *SMN1* duplications were associated with ALS susceptibility (odds ratio [OR] = 2.07, 95% confidence interval [CI] = 1.34 - 3.20. (Blauw et al., 2011)). A meta-analysis of all previously published data, taking possible heterogeneity between studies into account, confirmed this association with *SMN1* duplications. Other work has shown that homozygous deletions of *SMN2* are associated

with sporadic adult-onset lower motor neuron disease (Echaniz-Laguna et al., 2002; Moulard et al., 1998). Homozygous deletions of *SMN2* were also found to be overrepresented in 110 ALS patients (16%) compared to 100 controls (4%) (Veldink et al., 2001). *SMN2* deletions were associated with shorter survival in this study. However, a study by the same group using more ALS and control samples and several other studies did not find a higher frequency of *SMN2* deletions in ALS patients versus controls (Corcia et al., 2006; Gamez et al., 2002; Moulard et al., 1998; Parboosingh et al., 1999; Veldink et al., 2005). The recent meta-analysis showed that there is no increased frequency of homozygous *SMN2* deletions in ALS patients, and that neither *SMN1* nor *SMN2* appear to influence survival or age at onset of disease (Blauw et al. 2011).

Homozygous deletions in *SMN1* or *SMN2* do not play a role in ALS but an abnormal copy number in *SMN1* could increase risk for ALS and it is important to study the consequences on protein level in brain and spinal cord of having three copies of *SMN1* in order to determine the potential damaging effect.

### 3.9 Vascular endothelial growth factor (VEGF)

VEGF, a protein that stimulates angiogenesis in response to hypoxia, was identified as a candidate gene for ALS based on the finding that a deletion in the hypoxia response element (HRE) in the promoter of this gene in mice, resulting in decreased VEGF expression, led to progressive motor neuron degeneration (Oosthuysen et al., 2001). In addition, *VEGF* gene delivery in muscle and VEGF overexpression prolongs survival in mutant *SOD1* transgenic mice. Furthermore, intracerebroventricular VEGF administration prolongs survival in mutant *SOD1* transgenic rats (Azzouz et al., 2004; Storkebaum et al., 2005; Wang et al., 2007). Finally, decreased expression of VEGF and its receptor VEGFR2 is observed in spinal cords of ALS patients (Brockington et al., 2006).

Sequencing of the *VEGF* gene and its promoter in ALS patients failed to identify ALS specific mutations (Brockington et al., 2005; Gros-Louis et al., 2003; Lambrechts et al., 2003). However, a large study in 750 ALS patients and over 1200 controls from Sweden, Belgium, and England found association between two haplotypes determined by three SNPs and an increased risk for ALS (Lambrechts et al., 2003). These haplotypes lowered the circulating levels of VEGF and *VEGF* transcription (Lambrechts et al., 2003). This association was replicated in a study with small sample size (Terry et al., 2004). In contrast, subsequent studies could not confirm the association between *VEGF* and ALS in Dutch, British, American, Italian, Polish and Chinese populations (Brockington et al., 2005; Chen et al., 2006; Del Bo et al., 2008a; Golenia et al., 2010; Van Vught et al., 2005; Zhang et al., 2006). Furthermore, a meta-analysis on several of these studies found no association between *VEGF* polymorphisms and ALS (Lambrechts et al., 2009). A study in German ALS patients identified an association of a *VEGF* SNP with sALS in women (Fernández-Santiago et al., 2006). A different SNP was associated with ALS in male patients in a large meta-analysis (Lambrechts et al., 2009). This suggests that the role of *VEGF* in ALS may be gender dependent. An association of *VEGF* SNPs with age of onset in ALS was also reported although no such association was observed in the meta-analysis (Chen et al., 2007; Lambrechts et al., 2009).

In summary, studies in rodent models suggest a role for VEGF in ALS, possibly as a therapeutic target. However, genetic studies do not yet provide conclusive evidence for a genetic role for VEGF in ALS, although gender dependent effects may exist.

### 3.10 Genome wide association studies in sporadic ALS

Several genome-wide association studies (GWAS) have been performed in sALS patients. These studies have generated association results that have been replicated in the same study but rarely in independent studies. Although several of the associated genes discussed below are plausible to contribute to ALS considering their functional roles, the lack of consistent replication results makes it difficult to firmly establish their role in sALS.

A GWAS in 276 ALS patients and 271 healthy controls identified 34 possible associated SNPs but none of these reached genome-wide significance after Bonferroni correction (Schymick et al., 2007). A SNP near the gene *FGGY* carbohydrate kinase domain containing (*FGGY*) was reported to be associated in a GWAS in 1152 ALS patients with an odds ratio of 1.35 (Dunckley et al., 2007). However, two replication studies in a total of 2478 sALS patients and 2744 controls did not detect this association (Fernández-Santiago et al., 2011; Van Es et al., 2009b). No mutations in *FGGY* were found by sequencing in 190 ALS patients (Daoud et al., 2010).

A GWAS in 461 ALS patients and 450 controls found a variant in the inositol 1, 4, 5-triphosphate receptor 2 gene (*ITPR2*) to be associated with ALS. This association was replicated in the same study in a cohort of 876 patients and 906 controls and in the combined analysis (Van Es et al., 2007). *ITPR2* has a role in glutamate-mediated neurotransmission, regulation of calcium concentration and apoptosis. However, the *ITPR2* association has not been found in a replication study and in subsequent GWAS (Chiò et al., 2009; Cronin et al., 2008; Fernández-Santiago et al., 2011; Laaksovirta et al., 2010; Shatunov et al., 2010; Van Es et al., 2009c).

Variation in the dipeptidyl-peptidase 6 (*DPP6*) gene was found to be significantly associated with sALS in a GWAS performed in a combined GWA data set from the USA and the Netherlands (Van Es et al., 2008). This association was replicated in three additional independent populations from The Netherlands, Sweden, and Belgium (Van Es et al., 2008). The same variant was the top hit in a joint analysis of GWA data sets in an Irish population and the same Dutch and American populations, although it did not reach genome-wide significance (Cronin et al., 2008). Upon addition of a Polish data set the association could not be replicated which could point to a population-specific effect (Cronin et al., 2009). In an Italian cohort of 266 ALS patients association of the same SNP was replicated (Del Bo et al., 2008b). However, subsequent replication studies and GWAS could not find evidence for a role of *DPP6* in ALS (Chiò et al., 2009; Daoud et al., 2010; Fogh et al., 2011; Laaksovirta et al., 2010; Li et al., 2009; Shatunov et al., 2010; Van Es et al., 2009c). Interestingly, in a genome scan for copy number variations, including 4434 ALS patients and over 14000 controls, a suggestive association was found for the *DPP6* locus (Blauw et al., 2010). Not much data is available on the function of *DPP6*, but it is expressed in brain and able to regulate the activity of neuropeptides and to bind A-type neuronal potassium channels (Nadal et al., 2003).

Another two-stage GWAS in sALS patients was unable to find any associated SNPs that reached genome-wide significance, although suggestive association was found on **chromosome 7p13.3** (Chiò et al., 2009).

Survival analysis in a GWAS using samples from the USA and Europe revealed that a CC genotype of a SNP in the kinesin-associated protein 3 (*KIFAP3*) gene conferred a 14-month survival advantage on ALS patients (Landers et al., 2009). Expression data using RNA from brain tissue and lymphoblasts of patients showed that the favorable genotype significantly

decreased KIFAP3 expression (Landers et al., 2009). However, two subsequent studies in two Italian cohorts could not replicate the finding that the CC genotype had a beneficial effect on survival or decreased KIFAP3 expression in ALS patients (Orsetti et al., 2011; Traynor et al., 2010). KIFAP3 is part of the trimeric kinesin 2 motor complex KIF3 which mediates binding between proteins and their cargo. It serves multiple functions including a role in mitosis and intracellular transport of organelles and proteins in various tissues including neurons (Haraguchi et al., 2006; Takeda et al., 2000).

The largest GWAS to date identified two loci, on **chromosome 9p21.2** and **19p13.11**, to be associated with sALS. The genetic variant in 19p13.11 maps to a haplotype within the boundaries of the *UNC13A* gene. Two studies failed to replicate this finding, but were underpowered, and more studies are needed to firmly establish genetic variation in *UNC13A* as being causative to sALS.

The association to chromosome 9p21.2 will be discussed in more detail in the following sections.

#### 4. ALS-FTD2 (9p13.2-21.3)

Several linkage studies associated **chromosome 9p** to ALS-FTD, designated as ALS-FTD2 (Table 3). The first two independent studies found linkage to locus 9p13.2-21.3 in a Dutch and a Scandinavian family (Morita et al., 2006; Vance et al., 2006). Subsequently, eight other linkage studies in families from Canada, France, Belgium, North-America, Australia and Wales showed association to regions on chromosome 9p13.1-q21 (Boxer et al., 2010; Gijssels et al., 2010; Le Ber et al., 2009; Luty et al., 2009; Momeni et al., 2006; Pearson et al., 2011; Valdmanis et al., 2007; Yan et al., 2006). Individuals in these families were diagnosed with ALS, FTD, and ALS-FTD. However, dementia, psychosis and Parkinsonism were also seen. Besides the co-occurrence of ALS and FTD in families, there is also considerable clinical overlap between ALS and FTD, i.e. mild cognitive abnormalities occur in up to 50% of ALS patients and in approximately 5% of ALS patients FTD is present with marked behavioral changes and language impairment (Elamin et al., 2011; Ringholz et al., 2005). Furthermore, ALS and FTD are both characterized by TDP-43 positive ubiquitinated cytoplasmic inclusions (Neumann et al., 2006). This strongly supports the idea that there is a common genetic contribution to the pathogenesis of both diseases.

A total of 41 genes, four micro RNAs, two pseudogenes, and a non-coding RNA in the associated chromosome 9p region have been screened for mutations but only in one study a premature stop codon in the intraflagellar transport 74 gene (*IFT-74*) was identified in two brothers from one family (Momeni et al., 2006). However, no mutations in *IFT-74* were identified in any of the other ALS-FTD families that were linked to chromosome 9p and it is therefore unlikely that this mutation is the underlying cause in these families.

Interestingly, a recent GWAS in sALS patients found association between ALS and chromosome 9p21.2. 2323 ALS patients and 9013 controls were genotyped and genome-wide significance was found for SNPs on these two loci (van Es et al., 2009c). This finding was replicated in a second, independent cohort of 2532 ALS patients and 5940 controls. The associated SNPs are in a 80-kb linkage disequilibrium (LD) block on chromosome 9 which overlaps with the common region found in the ALS-FTD linkage studies (Figure 1).



Study	Linkage region	Families	Country/ Region	fALS	FTD	ALS- FTD	Genes screened	Mutations
Yan et al. 2006	9p13.3-p22.1 (D9S1684-D9S1678)	15	N.K.	N.K.	N.K.	N.K.	27	None
Morita et al. 2006	9p13.2-p21.3 (D9S1870-D9S1791)	1	Scandinavia	5	9	-	2	None
Vance et al. 2006	9p13.2-p21.2 (D9S2154-D9S1874)	1	The Netherlands	7	2	3	3	None
Momeni et al. 2006	9p13.2-p22.2 (D9S157-D9S1874)	2	North-America	1	-	9	14	p.Q342X in IFT-74
Valdmanis et al. 2007	9p13.3-p22.2 (D9S157-D9S1805)	2	Canada/ France	14	3	4	4	None
Le Ber et al. 2009	9p11.2-p21.2 (AFM218xg11-D9S301)	6	France	9	10	12	29 + 4 miRNAs	None
Luty et al. 2008	9p21.2-q21 (D9S169-D9S167)	1	Australia	2	5	2	11	None
Gijselink et al. 2010	9p22.3-q21 (D9S235-D9S257)	1	Belgium	1	8	-	17	None
Boxer et al. 2010	9p21.2-p23 (D9S1808-D9S251)	1	USA	2	5	3	10	None
Pearson et al. 2011	9p21.2-p21.2	1	Wales	2	5	1	8	None

Table 3. Overview of linkage studies in ALS-FTD families. N.K. = not known



Fig. 1. Schematic overview of the associated regions found by linkage studies and GWAS.

Since this initial report several other GWAS in ALS patients have replicated the association to chromosome 9p21.2. In a GWAS performed on 405 Finnish ALS patients, of whom 93 patients had fALS, and 497 control individuals two association peaks were identified (Laaksovirta et al., 2010). One peak corresponded to the autosomal recessive D90A allele of the SOD1 gene. The other was identified in a 232-kb LD block on chromosome 9p21.2. The association signals in this study were mainly driven by the 93 fALS patients. A 42-SNP risk haplotype across the chromosome 9p21 locus was shared between 41 fALS cases with an odds ratio of 21.0 (Laaksovirta et al., 2010). In another GWAS in an ALS cohort from the UK

consisting of 599 ALS patients and 4144 control individuals two SNPs on chromosome 9p21.2 were found to be associated with ALS (Shatunov et al., 2010). A joint analysis including 4132 ALS patients and 8425 controls from this UK cohort and from previously published data from the UK, USA, Netherlands, Ireland, Italy, France, Sweden, and Belgium also showed significant association to the locus on chromosome 9p21.2 (Shatunov et al., 2010). In addition, replication of one of the associated SNPs on chromosome 9p21.2 was found in a GWAS performed in FTD patients when analyzing the ALS-FTD patients only. A different SNP in this locus was significantly associated with FTD (Rollinson et al., 2011). A trend towards significant genome-wide association between chromosome 9p21.2 and FTD was found when analyzing 426 FTD patients with TDP-43 pathology without mutations in the progranulin gene and 2509 control individuals (Van Deerlin et al., 2009). A replication study in Chinese and Japanese sALS patients failed to find association to one of the previously associated SNPs on chromosome 9p21.2 but this might be due to a lack of power (Iida et al., 2011).

In summary, linkage studies in ALS-FTD families and GWAS in sALS, ALS-FTD and FTD patients provide compelling evidence for a role of chromosome 9p21.2 in ALS and/or FTD. As mentioned, recently two studies identified a GGGGCC hexanucleotide repeat expansion in intron 1 of the *C9ORF72* gene as the cause of chromosome 9p-linked ALS-FTD (Dejesus-Hernandez et al., 2011; Renton et al., 2011).

## 5. Gene function

A hexanucleotide repeat expansion in the *C9ORF72* gene has recently been identified as the cause of chromosome 9p-linked ALS-FTD. The mechanism as to how this expanded repeat causes ALS is unknown. No causal mutations in *UNC13a* have been identified in ALS patients to date. Close examination of the reported function(s) of the proteins encoded by the *C9ORF72* and *UNC13a* gene may help to design strategies for determining the functional role of these loci in ALS and/or FTD.

In this section the current knowledge of the function of these genes will be discussed in light of a possible contribution to ALS pathogenesis.

### 5.1 Chromosome 9 open reading frame 72

The *C9ORF72* gene encodes a protein of 481 amino acids. Alternative splicing of this gene is thought to produce five isoforms of which three are protein coding. Isoform 1 contains the entire sequence and consists of 481 amino acids, while isoform 2 and 3 have an asparagine to lysine change at amino acid 222 which results in the truncation of amino acids 223 to 481. Thus far, no *C9ORF72* protein has been detected and nothing is known about the function of *C9ORF72*.

The *C9ORF72* gene has been sequenced in four linkage studies in 39 patients from different families, but no mutations have been identified. No changes in splicing, small deletions or duplications were detected in patients from an ALS-FTD family (Boxer et al., 2010). The gene has been sequenced in 16 sALS patients and 16 controls but no variants specific for sALS were identified (Laaksovirta et al., 2010). Hexanucleotide repeat expansions were recently found to be the most common cause of fALS and familial FTD and were also identified in sALS patients (Dejesus-Hernandez et al., 2011; Renton et al., 2011). The functional consequence of these repeat expansions are however unknown.

Further studies will be needed to characterize the C9ORF72 protein and to establish the consequences of the intronic repeat on ALS pathogenesis.

### 5.2 UNCoordinated 13 homolog A (UNC13a)

UNC13a is a member of UNC13 family of presynaptic proteins. The protein consists of 1791 amino acids but several isoforms exist. It contains a zinc-finger like C1 domain that is homologous to a diacylglycerol and phorbol ester binding region of protein kinase C (PKC), three C2 domains that are similar to the calcium binding regulatory regions of PKC and synaptotagmin, a calmodulin binding domain and two Munc homology domains (Basu et al., 2005).

In mammals, the Munc13 family comprises four homologous members, Munc13-1, Munc13-2, Munc13-3, and Munc13-4. Deletion mutants of Munc13-1 in mice, the murine homologue of UNC13a, shows that the protein is needed for presynaptic vesicle maturation and fusion competence in glutamergic hippocampal neurons (Augustin et al., 1999). GABA-ergic neurons in the hippocampus show no spontaneous or evoked synaptic transmission in absence of both Munc13-1 and Munc13-2 (Varoqueaux et al., 2002). Neuromuscular junction (NMJ) axon terminals contain Munc13-1 and a splice variant of Munc13-2 (Varoqueaux et al., 2005). Mice deficient in Munc13 due to a double knockout of Munc13-1 and Munc13-2 form specialized neuromuscular endplates. However, the distribution, size and shape of these synapses are altered. Also, muscle morphology is abnormal and a larger number of motor neurons is present in the spinal cord in Munc13-1/2 knockout mice, probably as a result of defective apoptosis. Furthermore, evoked synaptic transmission is impaired in these mutants but spontaneous transmission is unchanged (Varoqueaux et al., 2005). This indicates that vesicle priming in NMJs is partially independent of Munc13-1 or Munc13-2. However, despite the unchanged spontaneous transmission, muscle innervation is aberrant in Munc13-1/2 knockout mice (Varoqueaux et al., 2005).

As exemplified by the defects observed in Munc13-1 and Munc13-1/2 knockout mice, it is plausible that a disruption in UNC13a expression affects motor neurons and muscle innervation. The effect of UNC13a on glutamate exocytosis is also interesting since Riluzole, the only drug with a proven effect on ALS, is a glutamate release inhibitor. Therefore, *UNC13a* is an interesting candidate gene to be investigated further for a role in ALS pathogenesis.

## 6. Conclusion and future research

The use of linkage analysis, candidate gene studies, and GWAS has led to the identification of several causal loci and genes for fALS and sALS. The overview above clearly shows the extent of heterogeneity in genes that underlie fALS, let alone sALS, illustrating the complex molecular basis of this disease. There is not one dominant biological process that is represented by these genes, although RNA-processing, axonal transport and synaptic dysfunction appear to emerge as being relevant in ALS etiology. Interestingly, several of the genes implicated in these processes are already known to be causal or have been implicated in other neurodegenerative diseases which suggests that there is, at least in part, a common underlying mechanism.

Since these findings explain only about a third of the genetic variability in fALS and a small percentage of the genetic contribution to sALS, there is a clear need for the identification of additional causal loci. This would require the collection of large family pedigrees with many affected individuals, which is difficult in ALS considering the adult onset with rapid disease progression. However, the development of next generation sequencing techniques provides a possible solution to this problem. Using exome and whole-genome sequencing, causal genes can be identified with a small number of affected and unaffected individuals as has been shown in several, mostly autosomal recessive disorders (Choi et al., 2009; Ng et al., 2009). Recently, exome sequencing in two affected individuals from the same family identified *VCP* as a causal gene for fALS, illustrating that this technique is a promising tool for gene identification in ALS as well (Johnson et al., 2010). In addition, the repeat expansion in *C9ORF72* was also discovered with the use of whole-genome sequencing (Renton et al., 2011).

The identification of causal genes for ALS has broadened our understanding of this motor neuron degenerative disease. Studying the function of associated genes in neurons and animal models has revealed several possible processes underlying ALS such as RNA processing, axonal transport, glutamate regulation, oxidative stress and synaptic dysfunction. However, the contribution of most genes to ALS pathogenesis has not been resolved. *SOD1* and *TDP-43* transgenic animal models have provided valuable insights into ALS pathogenesis. Further research using existing animal models of ALS associated genes and the generation of new animal models are needed to further determine their role in the disease. Generation of animal models harbouring repeat expansions in *C9ORF72* and *ATXN2* could help to reveal the pathogenic mechanisms behind these repeats. The effect of overexpression or knockdown of ALS associated genes and the expression of repeat expansions in motor neurons or motor neuron-like cell lines on protein aggregation and cell survival could also help to unravel the contribution of these genes to ALS. In addition, some associated genes (e.g. *DCTN1*, *PON1/2/3*, *TAF15*, and *VCP*) remain to be sequenced in larger cohorts from different populations in order to determine the actual contribution of these genes to ALS.

Additional new strategies in sALS include a more network oriented approach to gene identification. It is possible to detect networks of genes, proteins and metabolites that are misregulated in ALS, or that determine disease progression. By searching for subtle genetic variation that drives these network perturbations, new genes might be identified that are hard to detect with GWAS. Also, the focus in ALS genetics thus far has been on common variation in exonic DNA. The regulatory part of the genome is challenging to study, but might be relevant as well. This also requires the combined analysis of gene-expression and protein data with data on genetic variation. In addition, recent studies show that tandem repeats in DNA might be also relevant, as exemplified by the *ATXN2* and *C9ORF72* findings. Typically, this type of variation is hard to detect by current high-throughput methods. Lastly, the type of copy number variation that has not yet been covered very well to date, including variation in microRNAs or inversions, deserves more attention.

In summary, impressive progress in the understanding of the genetics of ALS has been made over the past several years with the identification of several causal genes. However, most of the genetic variability underlying ALS remains to be identified. The use of deep sequencing techniques and functional research will be needed to further broaden our understanding of ALS pathogenesis.

## 7. Acknowledgements

This work has received funding from the European Community's Health Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 259867, VSB fonds, EURO-MOTOR FP7, The Netherlands ALS Foundation (J.H.V. and L.H.v.d.B.), Neuroscience and Cognition Utrecht (NCU), the Prinses Beatrix Fonds (Kersten Foundation) and the Adessium Foundation (R.J.P., J.H.V. and L.H.v.d.B.). J.H.V. is supported by the Brain Foundation of The Netherlands and J.H.V, R.J.P., and M.K are supported by the Thierry Latran Foundation.

## 8. References

- Al-Chalabi A., et al. (2010). An estimate of amyotrophic lateral sclerosis heritability using twin data. *Journal of Neurology, Neurosurgery, and Psychiatry*, Vol. 81, No. 12, (December 2010), pp. 1342-1346, ISSN 0022-3050
- Al-Saif A., Al-Mohanna F. & Bohlega S. (2011). A mutation in Sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. *Annals of Neurology*, 2011, Ahead of print, ISSN 0364-5134
- Augustin I., et al. (1999). Munc13-1 is essential for fusion competence of glutamergic synaptic vesicles. *Nature*, Vol. 400, No. 29, (July 2009), pp. 457-461, ISSN 0028-0836
- Avemaria F., et al. (2011). Mutation in the senataxin gene found in a patients affected by familial ALS with juvenile onset and slow progression. *Amyotrophic Lateral Sclerosis*, Vol. 12, No. 3, (May 2011), pp. 228-230, ISSN 1748-2968
- Azzouz M., et al. (2004). VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. *Nature*, Vol. 429, No. 6990, (May 2004), pp. 413-417, ISSN 0028-0836
- Badouel C & McNeill H. (2011). Snapshot: The hippo signaling pathway. *Cell*, Vol. 145, No. 3, (April 2011), pp. 484-484.e1, ISSN 1097-4172
- Bandyopadhyay S., et al. (2010). A human MAP kinase interactome. *Nature Methods*, Vol. 7, No. 10, (October 2010), pp. 801-805, ISSN 1548-7091
- Basu J., et al. (2005). A minimal domain responsible for Munc13 activity. *Nature Structural & Molecular Biology*, Vol. 12, No. 11, (November 2005), pp. 1017-1018, ISSN 1545-9993
- Bäumer D., et al. (2010). Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. *Neurology*, Vol. 75, No. 7, (August 2010), pp. 611-618, ISSN 0028-3878
- Beaulieu JM, Nguyen MD & Julien JP. (1999). Late onset of motor neurons in mice overexpressing wild-type peripherin. *Journal of Cell Biology*, Vol. 147, No. 3, (November 1999), pp. 531-544, ISSN 0021-9525
- Belly A., et al. (2010). CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines. *Journal of Cell Science*, Vol. 123, Pt. 17, (September 2010), pp. 2943-2954, ISSN 0021-9533
- Belzil VV., et al. (2009). Mutations in FUS cause FALS and SALS in French and French Canadian populations. *Neurology*, Vol. 73, No. 15, (October 2009), pp. 1176-1179, ISSN 0028-3878
- Belzil VV., et al. (2010). Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis. *Neurobiology of Aging*, Vol. 32, No. 3, (March 2011), pp. 555.e13-4, ISSN 1558-1497

- Benajiba L., et al. (2009). TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. *Annals of Neurology*, Vol. 65, No. 4, (April 2009), pp. 470-473, ISSN 0364-5134
- Blauw HM., et al. (2010). A large genome scan for rare CNVs in amyotrophic lateral sclerosis. *Human Molecular Genetics*, Vol. 19, No. 20, (October 2010), pp. 4091-4099, ISSN 0964-6906
- Blauw HM., et al. *Neurology*, 2011;in press
- Bosco DA., et al. (2010). Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. *Human Molecular Genetics*, Vol. 19, No. 21, (November 2010), pp. 4160-4175, ISSN 0964-6906
- Bose JK., et al. (2008). TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. *Journal of Biological Chemistry*, Vol. 283, No. 43, (October 2008), pp. 28852-28859, ISSN 0021-9258
- Boxer AL., et al. (2010). Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. *Journal of Neurology, Neurosurgery and Psychiatry*, Vol.82, No.2, (February 2011), pp.196-203, ISSN 0022-3050
- Brockington A., et al. (2005). Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis. *Neurogenetics*, Vol. 6, No. 2, (May 2005), pp. 101-104, ISSN 1364-6745
- Brockington A., et al. (2006). Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. *Journal of Neuropathology and Experimental Neurology*, Vol. 65, No. 1, (January 2006), pp. 26-36, ISSN 0022-3069
- Broeke JHP., et al. (2010). Munc18 and Munc13 regulate early neurite outgrowth. *Biology of the Cell*, Vol. 102, No. 8, (June 2010), pp. 479-488, ISSN 0248-4900
- Buratti E & Baralle FE. (2010). The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. *RNA Biology*, Vol. 7, No. 4, (July-August 2010), pp. 420-429, ISSN 1547-6286
- Byrne S., et al. (2010). Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. *Journal of Neurology, Neurosurgery, and Psychiatry*, Vol. 82, No. 6, (June 2011), pp. 623-627, ISSN 0022-3050
- Cai H., et al. (2008). ALS2/alsin knockout mice and motor neuron diseases. *Neurodegenerative diseases*, Vol. 5, No. 6, (2008), pp. 359-366, ISSN 1660-2854
- Calvo A., et al. (2010). Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity? *CNS & Neurological Disorders Drug Targets*, Vol. 9, No. 3, (July 2010), pp. 325-330, ISSN 1871-5273
- Chance PF., et al. (1998). Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. *American Journal of Human Genetics*, Vol. 62, No. 3, (March 1998), pp. 633-640, ISSN 0002-9297
- Chen D., et al. (2007). Association of polymorphisms in vascular endothelial growth factor gene with the age of onset of amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*, Vol. 8, No. 3, (June 2007), pp. 144-149, ISSN 1748-2968
- Chen HJ., et al. (2010). Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. *Journal of Biological Chemistry*, Vol. 285, No. 51, (December 2010), pp. 40266-40281, ISSN 0021-9258

- Chen W., et al. (2006). Lack of association of VEGF promoter polymorphisms with sporadic ALS. *Neurology*, Vol. 67, No. 3, (August 2006), pp. 508-510, ISSN 0028-3878
- Chen Y., et al. (2011). Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. *Neurobiology of Aging*, 2011, Ahead of print, ISSN 0197-4580
- Chen YZ., et al. (2004). DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). *American Journal of Human Genetics*, Vol. 74, No. 6, (June 2004), pp. 1128-1135, ISSN 0002-9297
- Chió A., et al. (1991). Risk factors in motor neuron disease: a case-control study. *Neuroepidemiology*, Vol. 10, No. 4, (1991), pp 174-184, ISSN 0251-5350
- Chiò A., et al. (2009). A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. *Human Molecular Genetics*, Vol. 18, No. 8, (April 2009), pp. 1524-1532, ISSN 0964-6906
- Choi M., et al. (2009). Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. *Proceedings of the National Academy of Sciences of the USA*, Vol. 106, No. 45, (November 2009), pp. 19096-19101, ISSN 0027-8424
- Chow CY., et al. (2007). Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. *Nature*, Vol. 448, No. 7149, (July 2007), pp. 68-73, ISSN 0028-0836
- Chow CY., et al. (2009). Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. *American Journal of Human Genetics*, Vol. 84, No. 1, (January 2009), pp. 85-88, ISSN 0002-9297
- Conforti FL., et al. (2007). A novel angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy. *Neuromuscular Disorders*, Vol. 18, No. 1, (January 2008), pp. 68-70, ISSN 0960-8966
- Coppedè F., et al. (2008). Lack of association between the APEX1 Asp184Glu polymorphism and sporadic amyotrophic lateral sclerosis. *Neurobiology of Aging*, Vol. 31, No. 2, (February 2010), pp. 353-355, ISSN 0197-4580
- Corbo M & Hays AP. (1992). Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. *Journal of Neuropathology and Experimental Neurology*, Vol. 51, No. 5, (September 1992), pp. 531-537, ISSN 0022-3069
- Corcia P., et al. (2002). Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. *Annals of Neurology*, Vol. 51, No. 2, (February 2002), pp. 243-246, ISSN 0364-5134
- Corcia P., et al. (2006). SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. *Neurology*, Vol. 67, No. 7, (October 2006), pp. 1147-1150, ISSN 0028-3878
- Corcia P., et al. (2009). The importance of the SMN genes in the genetics of sporadic ALS. *Amyotrophic Lateral Sclerosis*, Vol. 10, No. 5-6, (October-December 2009), pp. 436-440, ISSN 1748-2968
- Corrado L., et al. (2007). Variations in the coding and regulatory sequences of the angiogenin (ANG) gene are not associated to ALS (amyotrophic lateral sclerosis) in the Italian population. *Journal of Neurological Sciences*, Vol. 258, No. 1-2, (July 2007), pp. 123-127, ISSN 0022-510X
- Corrado L., et al. (2009). High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. *Human Mutation*, Vol. 30, No. 4, (April 2009), pp. 688-694, ISSN 1059-7794

- Corrado L., et al. (2009). Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. *Journal of Medical Genetics*, Vol. 47, No. 3, (March 2010), pp. 190-194, ISSN 0022-2593
- Corrado L., et al. (2010). A novel peripherin gene (PRPH) mutation identified in one sporadic amyotrophic lateral sclerosis patients. *Neurobiology of Aging*, Vol. 32, No. 3, (March 2011), pp. 552.e1-6, ISSN 0197-4580
- Costa L.G., et al. (2005). Modulation of paraoxonase (PON1) activity. *Biochemical Pharmacology*, Vol. 69, No. 4, (February 2005), pp. 541-550, ISSN 0006-2952
- Couillard-Després S., et al. (1998). Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. *Proceedings of the National Academy of Sciences of the USA*, Vol. 95, No. 16, (August 1998), pp. 9626-9630, ISSN 0027-8424
- Cox L.E., et al. (2010). Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). *PLoS One*, Vol. 5, No. 3, (March 2010), e9872, ISSN 1932-6203
- Cronin S., et al. (2007). Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*, Vol. 78, No. 9, (September 2007), pp. 984-986, ISSN 0022-3050
- Cronin S., et al. (2007). A genome-wide association study of sporadic ALS in a homogenous Irish population. *Human Molecular Genetics*, Vol. 17, No. 5, (March 2008), pp. 768-774, ISSN 0964-6906
- Cronin S., et al. (2008). Screening for replication of genome-wide SNP associations in sporadic ALS. *European Journal of Human Genetics*, Vol. 17, No. 2, (February 2009), pp. 213-218, ISSN 1018-4813
- Crow M.K. (2010). Type I interferon in organ-targeted autoimmune and inflammatory diseases. *Arthritis Research and Therapy*, Vol.12, (2010), Suppl.1:S5, ISSN 1478-6354
- Da Cruz S & Cleveland DW. (2011). Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. *Current Opinion in Neurobiology*, 2011: Ahead of print
- Daoud H., et al. (2010). Analysis of DPP6 and FGGY as candidate genes for amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*, Vol. 11, No. 4, (August 2011), pp. 389-391, ISSN 1748-2968
- Daoud H., et al. (2011). Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. *Archives of Neurology*, Vol. 68, No. 6, (June 2011), pp. 739-742, ISSN 0003-9942
- Dedoni S, Olanas MC & Onali P. (2010). Interferon- $\beta$  induces apoptosis in human SH-Sy5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway. *Journal of Neurochemistry*, Vol. 115, No. 6, (December 2010), pp. 1421-1433, ISSN 0022-3042
- Dejesus-Hernandez M et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron*, September 2011, Ahead of print.
- Del Bo R., et al. (2006). Absence of angiogenic genes modification in Italian ALS patients. *Neurobiology of Aging*, Vol. 29, No. 2, (February 2008), pp. 314-316, ISSN 0197-4580
- Del Bo R., et al. (2008). DPP6 gene variability confers increased risk of developing sporadic amyotrophic lateral sclerosis in Italian patients. *Journal of Neurology, Neurosurgery, and Psychiatry*, Vol. 79, No. 9, (September 2008), pp. 1085, ISSN 0022-3050



- Del Bo R., et al. (2011). Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*, 2001, Ahead of print, ISSN 0022-3050
- Delisle MB & Carpenter S. (1984). Neurofibrillary axonal swellings and amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*, Vol. 63, No. 2, (February 1984), pp. 241-250, ISSN 0022-510X
- Deng HX., et al. (2010). FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. *Annals of Neurology*, Vol. 67, No. 6, (June 2010), pp. 739-748, ISSN 0364-5134
- Deng HX., et al. (2011). Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. *Nature*, Vol. 477, No. 7363, (August 2011), pp. 211-215, ISSN 0028-0836
- De Weerd NA, Samarajiwa SA & Hertzog PJ. (2007). Type I interferon receptors: biochemistry and biological functions. *Journal of Biological Chemistry*, Vol. 282, No. 28, (July 2007), pp. 20053-20057, ISSN 0021-9258
- Dickson SP., et al. (2010). Rare variants create synthetic genome-wide associations. *PLoS Biology*, Vol. 8, No. 1, (January 2010), e1000294, ISSN 1544-9173
- Dion PA, Daoud H & Rouleau GA. (2009). Genetics of motor neuron disorders: new insights into pathogenic mechanisms. *Nature Reviews. Genetics*, Vol. 10, No. 11, (November 2009), pp. 769-782, ISSN 1471-0056
- Dormann D., et al. (2010). ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. *EMBO Journal*, Vol. 29, No. 16, (August 2010), pp. 2841-2857, ISSN 0261-4189
- Draganov DI., et al. (2000). Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. *Journal of Biological Chemistry*, Vol. 275, No. 43, (October 2000), pp. 33435-33442, ISSN 0021-9258
- Dunckley T., et al. (2007). Whole-genome analysis of sporadic amyotrophic lateral sclerosis. *New England Journal of Medicine*, Vol. 357, No. 8, (August 2007), pp. 775-788, ISSN 0028-4793
- Echaniz-Laguna A., et al. (2002). Homozygous exon 7 deletion of the SMN centromeric gene (SMN2): a potential susceptibility factor for adult-onset lower motor neuron disease. *Journal of Neurology*, Vol. 249, No. 3, (March 2002), pp. 290-293, ISSN 0340-5354
- Eggert C., et al. (2006). Spinal muscular atrophy: the RNP connection. *Trends in Molecular Medicine*, Vol. 12, No. 3, (March 2006), pp. 113-121, ISSN 1471-4914
- Elamin M., et al. (2011). Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. *Neurology*, Vol. 76, No. 14, (April 2011), pp. 1263-1269, ISSN 0028-3878
- Elden AC., et al. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature*, Vol. 466, No.7310, (August 2010), pp.1069-1075, ISSN 0028-0836
- Ewing RM., et al. (2007). Large-scale mapping of human protein-protein interactions by mass spectrometry. *Molecular Systems Biology*, Vol. 3, (2007), pp. 89, ISSN 1744-4292
- Farrer MJ., et al. (2009). DCTN1 mutations in Perry syndrome. *Nature Genetics*, Vol. 41, No. 2, (February 2009), pp. 163-165, ISSN 1061-4036

- Feder JN., et al. (1998). The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 95, No. 4, (February 1998), pp.1472-1477, ISSN 0027-8424
- Fernández-Santiago R., et al. (2006). Possible gender-dependent association of vascular endothelial growth factor (VEGF) gene and ALS. *Neurology*, Vol. 66, No. 12, (June 2006), pp. 1929-1931, ISSN 0028-3878
- Fernández-Santiago R., et al. (2009). Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. *Journal of Neurology*, Vol. 256, No. 8, (August 2009), pp. 1337-1342, ISSN 1351-5101
- Fernández-Santiago R., et al. (2009). No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. *Neurobiology of Aging*, Vol. 32, No. 3, (March 2011), pp. 551.e1-4, ISSN 0197-4580
- Figlewicz DA., et al. (1994). Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. *Human Molecular Genetics*, Vol. 3, No. 10, (October 1994), pp. 1757-1761, ISSN 0964-6906
- Fishel ML & Kelley MR. (2007). The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. *Molecular Aspects of Medicine*, Vol. 28, No. 3-4, (June-August 2007), pp. 375-395, ISSN 0098-2997
- Fogh I., et al. (2009) No association of DPP6 with amyotrophic lateral sclerosis in an Italian population. *Neurobiology of Aging*, Vol. 32, No. 5, (May 2011), pp. 966-967, ISSN 0197-4580
- Gamez J., et al. (2002). Survival and respiratory decline are not related to homozygous SMN2 deletions in ALS patients. *Neurology*, Vol. 59, No. 9, (November 2002), pp. 1456-1460, ISSN 0028-3878
- Gavrilov DK., et al. (1998). Differential SMN2 expression associated with SMA severity. *Nature Genetics*, Vol. 20, No. 3, (November 1998), pp. 230-231, ISSN 1061-4036
- Gellera C., et al. (2007). Identification of new ANG gene mutations in a large cohort of Italian patients with amyotrophic lateral sclerosis. *Neurogenetics*, Vol. 9, No. 1, (February 2008), pp. 33-40, ISSN 1364-6745
- Gijssels I., et al. (2010). Identification of 2 loci at chromosome 9 and 14 in a multiplex family with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Archives of Neurology*, Vol. 67, No. 5, (May 2010), pp. 606-616, ISSN 0003-9942
- Giordano G., et al. (2011). Paraoxonase 2 (PON2) in the mouse central nervous system: A neuroprotective role? *Toxicology and Applied Pharmacology*, (February 2011), Ahead of print, ISSN 0041-008X
- Gitcho MA., et al. (2009). VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. *Journal of Biological Chemistry*, Vol. 284, No. 18, (May 2009), pp. 12384-12398, ISSN 0021-9258
- Gitcho MA., et al. (2009). TARDBP 3'UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. *Acta Neuropathologica*, Vol. 118, No. 5, (November 2009), pp. 633-645, ISSN 0001-6322
- Goodall EF., et al. (2005). Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. *Neurology*, Vol. 65, No. 6, (September 2005), pp. 934-937, ISSN 0028-3878

- Golenia A., et al. (2010). Lack of association between VEGF gene polymorphisms and plasma VEGF levels and sporadic ALS. *Neurology*, Vol. 75, No. 22, (November 2010), pp. 2035-2037, ISSN 0028-3878
- Greenway MJ., et al. (2004). A novel candidate region for ALS on chromosome 14q11.2. *Neurology*, Vol. 63, No. 10, (November 2004), pp. 1936-1938, ISSN 0028-3878
- Greenway MJ., et al. (2006). ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. *Nature Genetics*, Vol. 38, No. 4, (April 2006), pp. 411-413, ISSN 1061-4036
- Groen EJ., et al. (2010). FUS mutations in amyotrophic lateral sclerosis in the Netherlands. *Archives of Neurology*, Vol. 67, No. 2, (February 2010), pp. 224-230, ISSN 0003-9942
- Grohmann K., et al. (2011). Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1. *Nature Genetics*, Vol. 29, No. 1, (September 2001), pp. 75-77, ISSN 1061-4036
- Gurney ME., et al. (1994). Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. *Science*, Vol. 264, No. 5166, (June 1994), pp. 1772-1775, ISSN 0036-8075
- Hadano S., et al. (2001). A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. *Nature Genetics*, Vol.29, No.2, (October 2001), pp.166-173, ISSN 1061-4036
- Hadano S., et al. (2005). Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking. *Human Molecular Genetics*, Vol. 15, No. 2, (January 2006), pp. 233-250, ISSN 0964-6906
- Hand CK., et al. (2001). A novel locus for familial amyotrophic lateral sclerosis on chromosome 18q. *The American Journal of Human Genetics*, Vol. 70, No.1, (January 2002), pp.251-256, ISSN 0002-9297
- Haraguchi K., et al. (2005). Role of the kinesin-2 family protein, KIF3, during mitosis. *Journal of Biological Chemistry*, Vol. 281, No. 7, (February 2006), pp. 4094-4099, ISSN 0021-9258
- Harley IT., et al. (2010). The role of genetic variation near interferon-kappa in systemic lupus erythematosus. *Journal of Biomedicine and Biotechnology*, 2010, ISSN 1110-7243
- Hayward C., et al. (1999). Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. *Neurology*, Vol. 52, No. 9, (June 1999), pp. 1899-1901, ISSN 0028-3878
- He X., et al. (2011). H63D polymorphism in the hemochromatosis gene is associated with sporadic amyotrophic lateral sclerosis in China. *European Journal of Neurology*, Vol. 18, No. 2, (February 2011), pp. 359-361, ISSN 1351-5101
- He CZ & Hays AP. (2004). Expression of peripherin in ubiquitinated inclusions of amyotrophic lateral sclerosis. *Journal of Neurological Sciences*, Vol. 217, No. 1, (January 2004), pp. 47-54, ISSN 0022-510X
- Hentati A., et al. (1994). Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. *Nature Genetics*, Vol. 7, No. 3, (July 1994), pp. 425-428, ISSN 1061-4036
- Hentati A., et al. (1998). Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. *Neurogenetics*, Vol. 2, No. 1, (December 1998), pp. 55-60, ISSN 1364-6745

- Hergovich A. (2011). MOB control: reviewing a conserved family of kinase regulators. *Cellular Signaling*, Vol. 23, No.9, (September 2011), pp.1433-1440, ISSN 0898-6568
- Hervas-Stubb S., et al. (2011). Direct effects of type I interferons on cells of the immune system. *Clinical Cancer Research*, Vol. 17, No. 9, (May 2011), pp. 2619-2627, ISSN 1078-0432
- Hewitt C., et al. (2010). Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. *Archives of Neurology*, Vol. 67, No. 4, (April 2010), pp. 455-461, ISSN 0003-9942
- Hirano M., et al. (2010). Senataxin mutations in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*, Vol. 12, No. 3, (May 2011), pp. 223-227, ISSN 1748-2968
- Horner RD., et al. (2003). Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. *Neurology*, Vol. 61, No. 6, (September 2003), pp. 742-749, ISSN 0028-3878
- Hosler BA., et al. (2000). Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. *Journal of the American Medical Association*, Vol. 284, No. 13, (October 2000), pp. 1664-1669, ISSN 0098-7484
- Huang C., et al. (2011). FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. *PLoS Genetics*, Vol. 7, No. 3, (March 2011), pp. e1002011, ISSN 1553-7404
- Huang EJ., et al. (2010). Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. *Brain Pathology*, Vol. 20, No. 6, (November 2010), pp. 1069-1076, ISSN 1015-6305
- Hutton M., et al. (1998). Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature*, Vol. 393, No. 6686, (June 1998), pp. 702-705, ISSN 0028-0836
- Iida A., et al. (2010). Large-scale screening of TARDBP mutation in amyotrophic lateral sclerosis. *Neurobiology of Aging*, 2010, Ahead of print
- Iida A., et al. (2011). Optineurin mutations in Japanese amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, (January 2011), ISSN 0022-3050
- Iida A., et al. (2011). Replication analysis of SNPs on 9p21.2 and 19p13.11 with amyotrophic lateral sclerosis in East Asians. *Neurobiology of Aging*, Vol. 32, No. 4, (April 2011), pp. 757.e13-4, ISSN 0197-4580
- Ilieva H, Polymenidou M & Cleveland DW. (2009). Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. *Journal of Cell Biology*, Vol. 187, No. 6, (December 2009), pp. 761-772, ISSN 0021-9525
- Imbert G., et al. (1996). Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. *Nature Genetics*, Vol. 14, No. 3, (November 1996), pp. 285-291, ISSN 1061-4036
- Ito D., et al. (2011). Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. *Annals of Neurology*, 2011, Ahead of print
- Jackson M., et al. (1996). Analysis of chromosome 5q13 genes in amyotrophic lateral sclerosis: homozygous NAIP deletion in a sporadic case. *Annals of Neurology*, Vol. 39, No. 6, (June 1996), pp. 796-800, ISSN 0364-5134
- Johnson JO., et al. (2010). Exome sequencing reveals VCP mutations as a cause of familial ALS. *Neuron*, Vol. 68, No. 5, (December 2010), pp. 857-864, ISSN 0896-6273

- Ju JS & Weihl CC. (2010). Inclusion body myopathy, Paget's disease of the bone and frontotemporal dementia: a disorder of autophagy. *Human Molecular Genetics*, Vol. 19, No. R1, (April 2010), pp. R38-45, ISSN 0964-6906
- Ju S., et al. (2011). A yeast model of FUS/TLS-dependent cytotoxicity. *PLoS Biology*, Vol. 9, No. 4, (April 2011), pp. e1001052, ISSN 1545-7885
- Kabashi E., et al. (2008). TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nature Genetics*, Vol. 40, No. 5, (May 2008), pp. 572-574, ISSN 1061-4036
- Kanekura K., et al. (2004). Alsin, the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants. *Journal of Biological Chemistry*, Vol. 279, No. 18, (April 2004), pp. 19247-19256, ISSN 0021-9258
- Kiernan MC., et al. (2011). Amyotrophic lateral sclerosis. *Lancet*, Vol. 377, No. 9769, (March 2011), pp. 942-955, ISSN 0140-6736
- Kisby GE, Milne J & Sweatt C. (1997). Evidence of reduced DNA repair in amyotrophic lateral sclerosis brain tissue. *Neuroreport*, Vol. 8, No. 6, (April 1997), pp. 1337-1340, ISSN 0959-4965
- Kohler RS., et al. (2010). Differential NDR/LATS interactions with the human MOB family reveal a negative role for human MOB2 in the regulation of human NDR kinases. *Molecular and Cellular Biology*, Vol. 30, No. 18, (September 2010), pp. 4507-4520, ISSN 1098-5549
- Kwiatkowski TJ Jr., et al. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science*, Vol. 323, No. 5918, (February 2009), pp. 1205-1208, ISSN 1095-9203
- Laaksovirta H., et al. (2010). Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. *Lancet Neurology*, Vol. 9, No. 10, (October 2010), pp. 978-985, ISSN 1474-4422
- LaFleur DW., et al. (2001). Interferon- $\kappa$ , a novel type I interferon expressed in human keratinocytes. *Journal of Biological Chemistry*, Vol. 276, No. 43, (October 2001), pp. 39765-39771, ISSN 0021-9258
- Lagier-Tourenne C, Polymenidou M & Cleveland DW. (2010). TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. *Human Molecular Genetics*, Vol. 19, No. R1, (April 2010), pp. R46-R64, ISSN 0964-6906
- Lambrechts D., et al. (2003). VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneuron against ischemic death. *Nature Genetics*, Vol. 34, No. 4, (August 2003), pp. 383-394, ISSN 1061-4036
- Lambrechts D., et al. (2009). Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. *Journal of Medical Genetics*, Vol. 46, No. 12, (December 2009), pp. 840-846, ISSN 0022-2593
- Landers JE., et al. (2008). A common haplotype within the PON1 promoter region is associated with sporadic ALS. *Amyotrophic Lateral Sclerosis*, Vol. 9, No. 5, (October 2008), pp. 306-314, ISSN 1748-2968
- Lariviere RC & Julien JP. (2004). Functions of intermediate filaments in neuronal development and disease. *Journal of Neurobiology*, Vol. 58, No. 1, (January 2004), pp. 131-148, ISSN 0022-3034

- Le Ber I., et al. (2009). Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. *Neurology*, Vol. 72, No. 19, (May 2009), pp. 1669-1676, ISSN 0028-3878
- Lee JA., et al. (2007). ESCRT-III dysfunction causes autophagosomes accumulation and neurodegeneration. *Current Biology*, Vol. 17, No. 18, (September 2007), pp. 1561-1567, ISSN 0960-9822
- Lee T., et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. *Human Molecular Genetics*, Vol. 20, No. 9, (May 2011), pp. 1697-1700, ISSN 0964-6906
- Lefebvre S., et al. (1997). Correlation between severity and SMN protein level in spinal muscular atrophy. *Nature Genetics*, Vol. 16, No. 3, (July 1997), pp. 265-269, ISSN 1061-4036
- Li XG., et al. (2009). Association between DPP6 polymorphism and the risk of sporadic amyotrophic lateral sclerosis in Chinese patients. *Chinese Medical Journal*, Vol. 122, No. 24, (December 2009), pp. 2989-2992, ISSN 0366-6999
- Lorson CL., et al. (1998). SMN oligomerization defect correlates with spinal muscular atrophy severity. *Nature Genetics*, Vol. 19, No. 1, (May 1998), pp. 63-66, ISSN 1061-4036
- Liu Y., et al. (2011). Mutant HFE H63D protein is associated with prolonged endoplasmic reticulum stress and increased neuronal vulnerability. *Journal of Biological Chemistry*, Vol. 286, No. 15, (April 2011), pp. 13161-13170, ISSN 0021-9258
- Luty AA., et al. (2008). Pedigree with frontotemporal lobar degeneration – motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. *BMC Neurology*, Vol. 8, (August 2008), pp. 32, ISSN 1471-2377
- Luty AA., et al. (2010). Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. *Annals of Neurology*, Vol. 68, No. 5, (November 2010), pp. 639-649, ISSN 0364-5134
- Mackness MI, Arrol S & Durrington PN. (1991). Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. *FEBS Letters*, Vol. 286, No. 1-2, (July 1991), pp. 151-154, ISSN 0014-5793
- McLean J., et al. (2010). Distinct biochemical signatures characterize peripherin isoform expression in both traumatic neuronal injury and motor neuron disease. *Journal of Neurochemistry*, Vol. 114, No. 4, (August 2010), pp. 1177-1192, ISSN 0022-3042
- Mersyanova IV., et al. (2000). A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilaments-light gene. *American Journal of Human Genetics*, Vol. 67, No. 1, (July 2000), pp. 37-46, ISSN 0002-9297
- Millecamps S., et al. (2010). SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. *Journal of Medical Genetics*, Vol. 47, No. 8, (August 2010), pp. 554-560, ISSN 0022-2593
- Millecamps S., et al. (2011). Screening of OPTN in French familial amyotrophic lateral sclerosis. *Neurobiology of Aging*, Vol. 32, No. 3, (March 2011), pp. 557.e11-3, ISSN 1558-1497
- Mitchell J., et al. (2010). Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. *Proceedings of the National Academy of Sciences of the USA*, Vol. 107, No. 16, (April 2010), pp. 7556-7561, ISSN 0027-8424

- Mitchell RM., et al. (2009). HFE polymorphisms affect cellular glutamate regulation. *Neurobiology of Aging*, Vol. 32, No. 6, (June 2011), pp. 1114-1123, ISSN 0197-4580
- Mizuno Y., et al. (2011). Peripherin partially localizes in Bunina bodies in amyotrophic lateral sclerosis. *Journal of Neurological Sciences*, Vol. 301, No. 1-2, (March 2011), pp. 14-18, ISSN 0022-510X
- Morahan JM., et al. (2006). A gene-environment study of the paraoxonase 1 gene and pesticides in amyotrophic lateral sclerosis. *Neurotoxicology*, Vol. 28, No. 3, (May 2007), pp. 532-540, ISSN 0161-813X
- Moreira MC., et al. (2004). Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. *Nature Genetics*, Vol. 36, No. 3, (March 2004), pp. 225-227, ISSN 1061-4036
- Morita M., et al. (2006). A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. *Neurology*, Vol. 66, No. 6, (March 2006), pp. 839-844, ISSN 0028-3878
- Moullard B., et al. (1998). Association between centromeric deletions of the SMN gene and sporadic adult-onset lower motor neuron disease. *Annals of Neurology*, Vol. 43, No. 5, (May 1998), pp. 640-644, ISSN 0364-5134
- Münch C., et al. (2004). Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. *Neurology*, Vol. 63, No. 4, (August 2004), pp. 724-726, ISSN 0028-3878
- Münch C., et al. (2005). Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. *Annals of Neurology*, Vol. 58, No. 5, (November 2005), pp. 777-780, ISSN 0364-5134
- Murayama H., et al. (2010). Mutations of optineurin in amyotrophic lateral sclerosis. *Nature*, Vol. 465, No. 7295, (May 2010), pp. 223-226, ISSN 0028-0836
- Nadal MS., et al. (2003). The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K<sup>+</sup> channels. *Neuron*, Vol. 37, No. 3, (February 2003), pp. 449-461, ISSN 0896-6273
- Nandar W & Connor JR. (2011). HFE gene variants affect iron in the brain. *Journal of Nutrition*, Vol. 141, No. 4, (April 2011), pp. 729S-739S, ISSN 0022-3166
- Nardelli B., et al. (2002). Regulatory effect of IFN- $\kappa$ , a novel type I IFN, on cytokine production by cells of the innate immune system. *Journal of Immunology*, Vol. 169, No. 9, (November 2002), pp. 4822-4830, ISSN 0022-1767
- Neumann M., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science*, Vol. 314, No. 5796, (October 2006), pp. 130-133, ISSN 1095-9203
- Nishimura AL., et al. (2004). A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. *American Journal of Human Genetics*, Vol. 75, No. 5, (November 2004), pp. 822-831, ISSN 0002-9297
- Nonis D., et al. (2008). Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. *Cellular Signalling*, Vol. 20, No. 10, (October 2008), pp. 1725-1739, ISSN
- Ng CJ., et al. (2001). Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. *Journal of Biological Chemistry*, Vol. 276, No. 48, (November 2001), pp. 44444-44449, ISSN 0021-9258

- Ng SB., et al. (2009). Targeted capture and massively parallel sequencing of 12 human exomes. *Nature*, Vol. 461, No. 7261, (September 2009), pp. 272-276, ISSN 0028-0836
- Oosthuysen B., et al. (2001). Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. *Nature Genetics*, Vol. 28, No. 2, (June 2001), pp. 131-138, ISSN 1061-4036
- Orlacchio A., et al. (2010). SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. *Brain*, Vol. 133, Pt. 2, (February 2010), pp. 591-598, ISSN 0006-8950
- Orozco G, Barrett JC & Zeggini E. (2010). Synthetic associations in the context of genome-wide association scan signals. *Human Molecular Genetics*, Vol. 19, No. R2, (October 2010), pp. R137-R144, ISSN 0964-6906
- Orrell RW., et al. (1997). The relationship of spinal muscular atrophy to motor neuron disease: investigation of SMN and NAIP gene deletions in sporadic and familial ALS. *Journal of Neurological Sciences*, Vol. 145, No. 1, (January 1997), pp. 55-61, ISSN 0022-510X
- Otomo A., et al. (2003). ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. *Human Molecular Genetics*, Vol. 12, No. 14, (July 2003), pp. 1671-1687, ISSN 0964-6906
- Parboosingh JS., et al. (1999). Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis. *Archives of Neurology*, Vol. 56, No. 6, (June 1999), pp. 710-712, ISSN 0003-9942
- Parkinson N., et al. (2006). ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). *Neurology*, Vol. 67, No. 6, (September 2006), pp. 1074-1077, ISSN 0028-3878
- Pasinelli P & Brown RH. (2006). Molecular biology of amyotrophic lateral sclerosis: insights from genetics. *Nature Reviews Neuroscience*, Vol. 7, No. 9, (September 2006), pp. 710-723, ISSN 1471-003X
- Paubel A., et al. (2008). Mutations of the ANG gene in French patients with amyotrophic lateral sclerosis. *Archives of Neurology*, Vol. 65, No. 10, (October 2008), pp. 1333-1336, ISSN 0003-9942
- Pearson JP., et al. (2010). Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. *Journal of Neurology*, Vol. 258, No. 4, (April 2011), pp. 647-655, ISSN 0340-5354
- Pestka S, Krause CD & Walter MR. (2004). Interferons, interferon-like cytokines, and their receptors. *Immunological reviews*, Vol. 202, (December 2004), pp. 8-32, ISSN 0105-2896
- Phillips T & Robberecht W. (2010). Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. *Lancet Neurology*, Vol. 10, No. 3, (March 2010), pp. 253-263, ISSN 1474-4422
- Puls I., et al. (2003). Mutant dynactin in motor neuron disease. *Nature Genetics*, Vol. 33, No. 4, (April 2003), pp. 455-456, ISSN 1061-4036
- Puls I., et al. (2005). Distal spinal and bulbar muscular atrophy caused by dynactin mutation. *Annals of Neurology*, Vol. 57, No. 5, (May 2005), pp. 687-694, ISSN 0364-5134
- Pulst SM., et al. (1996). Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. *Nature Genetics*, Vol. 14, No. 3, (November 1996), pp. 269-276, ISSN 1061-4036



- Ralser M., et al. (2004). An integrative approach to gain insights into the cellular function of human ataxin-2. *Journal of Molecular Biology*, Vol. 346, No. 1, (February 2005), pp. 203-214, ISSN 0022-2836
- Reaume AG., et al. (1996). Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. *Nature Genetics*, Vol. 13, No. 1, (May 1996), pp. 43-47, ISSN 1061-4036
- Renton AE et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron*, September 2011, Ahead of print
- Restagno G., et al. (2007). HFE H63D polymorphism is increase in patients with amyotrophic lateral sclerosis of Italian origin. *Journal of Neurology, Neurosurgery and Psychiatry*, Vol. 78, No. 3, (March 2007), pp. 327, ISSN 0022-3050
- Rezaie T., et al. (2002). Adult-onset primary open-angle glaucoma caused by mutations in optineurin. *Science*, Vol. 295, No. 5557, (February 2002), pp.1077-1079, ISSN 1095-9203
- Ricci C., et al. (2010). Lack of association of PON polymorphisms with sporadic ALS in an Italian population. *Neurobiology of Aging*, Vol. 32, No. 3, (March 2011), pp. 552.e7-13, ISSN 1558-1497
- Ringholz GM., et al. (2005). Prevalence and patterns of cognitive impairment in sporadic ALS. *Neurology*, Vol. 65, No. 4, (August 2005), pp. 586-590, ISSN 0028-3878
- Robertson J., et al. (2003). A neurotoxic peripherin splice variant in a mouse model of ALS. *Journal of Cell Biology*, Vol. 160, No. 6, (March 2003), pp. 939-949, ISSN 0021-9525
- Rollinson S., et al. (2011). Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. *Neurobiology of Aging*, Vol. 32, No. 4, (April 2011), pp. 758.e1-7, ISSN 0197-4580
- Rooke K., et al. (1996). Analysis of the KSP repeat of the neurofilament heavy subunit in familial amyotrophic lateral sclerosis. *Neurology*, Vol. 46, No. 3, (March 1996), pp. 789-790, ISSN 0028-3878
- Rosen DR., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature*, Vol. 362, No. 6415, (March 1993), pp. 59-62, ISSN 0028-0836
- Ross OA., et al. (2011). Ataxin-2 repeat-length variation and neurodegeneration. *Human Molecular Genetics*, Vol. 20, No. 16, (August 2011), pp. 3207-3212, ISSN 0964-6906
- Rual JF., et al. (2005). Towards a proteome-scale map of the human protein-protein interaction network. *Nature*, Vol. 437, No. 7062, (October 2005), pp. 1173-1178, ISSN 0028-0836
- Rutherford AC., et al. (2006). The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport. *Journal of Cell Science*, Vol. 119, Pt. 19, (October 2006), pp. 3944-3957, ISSN 0021-9533
- Saeed M., et al. (2006). Paraoxonase cluster polymorphisms are associated with sporadic ALS. *Neurology*, Vol. 67, No. 5, (September 2006), pp. 771-776, ISSN 0028-3878
- Sahlender DA., et al. (2005). Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis. *Journal of Cell Biology*, Vol. 169, No. 2, (April 2005), pp. 285-295, ISSN 0021-9525
- Salinas S., et al. (2008). Hereditary spastic paraplegia: clinical features and pathogenic mechanisms. *Lancet Neurology*, Vol. 7, No. 12, (December 2008), pp. 1127-1138, ISSN 1474-4422


- Sanpei K., et al. (1996). Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. *Nature Genetics*, Vol. 14, No. 3, (November 1996), pp. 277-284, ISSN 1061-4036
- Sapp PC., et al. (2003). Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. *American Journal of Human Genetics*, Vol. 73, No. 2, (August 2003), pp. 397-403, ISSN 0002-9297
- Schmitt-John T., et al. (2005). Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobler mouse. *Nature Genetics*, Vol. 37, No. 11, (November 2005), pp. 1213-1215, ISSN 1061-4036
- Schymick JC., et al. (2007). Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. *Lancet Neurology*, Vol. 6, No. 4, (April 2007), pp. 322-328, ISSN 1474-4422
- Sebastià J., et al. (2009). Angiogenin protects motoneurons against hypoxic injury. *Cell Death and Differentiation*, Vol. 16, No. 9, (September 2009), pp. 1238-1247, ISSN 1350-9047
- Shaikh AY & Martin LJ. (2002). DNA base-excision repair enzyme apurinic/apyrimidinic endonuclease/redox factor-1 is increased and competent in the brain and spinal cord of individuals with amyotrophic lateral sclerosis. *Neuromolecular Medicine*, Vol. 2, No. 1, (2002), pp. 47-60, ISSN 1535-1084
- Shatunov A., et al. (2010). Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. *Lancet Neurology*, Vol. 9, No. 10, (October 2010), pp. 986-994, ISSN 1474-4422
- Shin JS., et al. (2008). NEFL Pro22Arg mutation in Charcot-Marie-Tooth disease type 1. *Journal of Human Genetics*, Vol. 53, No. 10, (2008), pp. 936-940, ISSN 1434-5161
- Siddique T., et al. (1998). X-linked dominant locus for late-onset familial amyotrophic lateral sclerosis. *American Journal of Human Genetics*, Vol. 63, Suppl. A308.
- Skibinski G., et al. (2005). Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. *Nature Genetics*, Vol. 37, No. 8, (August 2005), pp. 806-808, ISSN 1061-4036
- Skourti-Stathaki K, Proudfoot NJ & Gromak N. (2011). Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. *Molecular Cell*, Vol. 42, No. 6, (June 2011), pp. 794-805, ISSN 1097-2765
- Skvortsova V., et al. (2004). Analysis of heavy neurofilament subunit gene polymorphism in Russian patients with sporadic motor neuron disease (MND). *European Journal of Human Genetics*, Vol. 12, No. 3, (March 2004), pp. 241-244, ISSN 1018-4813
- Slowik A., et al. (2006). Paraonase gene polymorphisms and sporadic ALS. *Neurology*, Vol. 67, No. 5, (September 2006), pp. 766-770, ISSN 0028-3878
- Sreedharan J., et al. (2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science*, Vol. 319, No. 5870, (March 2008), pp. 1668-1672, ISSN 1095-9203
- Stevanin G., et al. (2007). Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. *Nature Genetics*, Vol. 39, No. 3, (March 2007), pp. 366-372, ISSN 1061-4036
- Storkebaum E., et al. (2005). Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. *Nature Neuroscience*, Vol. 8, No. 1, (January 2005), pp. 85-92, ISSN 1097-6256

- Subramanian V, Crabtree B & Acharya KR. (2007). Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons. *Human Molecular Genetics*, Vol. 17, No. 1, (January 2008), pp. 130-149, ISSN 0964-6906
- Sugihara K., et al. (2011). Screening for OPTN mutations in amyotrophic lateral sclerosis in a mainly Caucasian population. *Neurobiology of Aging*, Vol. 32, No. 10, (October 2011), pp. 1923.e9-1923.e10, ISSN 1558-1497
- Sun Z., et al. (2011). Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. *PLoS Biology*, Vol. 9, No. 4, (April 2011), pp. e1000614, ISSN 1545-7885
- Sutedja NA., et al. (2007). The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. *Archives of Neurology*, Vol. 64, No. 1, (January 2007), pp. 63-67, ISSN 0003-9942
- Swarup V., et al. (2011). Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. *Brain*, 2011, Ahead of print.
- Takeda S., et al. (2000). Kinesin superfamily protein 3 (KIF3) motor transports fodrin-associating vesicles important for neurite building. *Journal of Cell Biology*, Vol. 148, No. 6, (March 2000), pp. 1255-1265, ISSN 0021-9525
- Terry PD., et al. (2004). VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). *Journal of Neurogenetics*, Vol. 18, No. 2, (April-June 2004), pp. 429-434, ISSN 0167-7063
- Teuling E., et al. (2007). Motor neuron disease-associated mutant vesicle-associated membrane protein-associated protein (VAP) B recruits wild-type VAPs into endoplasmic reticulum-derived tubular aggregates. *Journal of Neuroscience*, Vol. 27, No. 36, (September 2007), pp. 9801-9815, ISSN 0270-6474
- Ticozzi N., et al. (2009). Mutational analysis of TARDBP in neurodegenerative disease. *Neurobiology of Aging*, 2009, Ahead of print.
- Ticozzi N., et al. (2011). Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. *American Journal of Medical Genetics B: Neuropsychiatric Genetics*, Vol. 156B, No. 3, (April 2011), pp. 285-290, ISSN 1552-485X
- Tomkins J., et al. (2000). Screening of AP endonuclease as a candidate gene for amyotrophic lateral sclerosis (ALS). *Neuroreport*, Vol.11, No. 8 (June 2000), pp. 1695-1697, ISSN 0959-4965
- Topp JD., et al. (2004). Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor. *Journal of Biological Chemistry*, Vol. 279, No. 23, (June 2004), pp. 24612-24623, ISSN 0021-9258
- Troy CM., et al. (1990). Regulation of peripherin and neurofilaments expression in regenerating rat motor neurons. *Brain Research*, Vol. 529, No. 1-2, (October 1990), pp. 232-238, ISSN 0006-8993
- Tudor EL., et al. (2010). Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology. *Neuroscience*, Vol. 167, No. 3, (May 2010), pp. 774-785, ISSN 0306-4522

- Valdmanis PN., et al. (2007). Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. *Archives of Neurology*, Vol. 64, No. 2, (February 2007), pp. 240-245, ISSN 0003-9942
- Valdmanis PN., et al. (2008). Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. *Neurology*, Vol. 71, No. 7, (August 2008), pp. 514-520, ISSN 0028-3878
- Valdmanis PN & Rouleau GA. (2008). Genetics of familial amyotrophic lateral sclerosis. *Neurology*, Vol. 70, No. 2, (January 2008), pp. 144-152, ISSN 0028-3878
- Van Blitterswijk M., et al. (2011). Novel optineurin mutations in sporadic amyotrophic lateral sclerosis patients. *Neurobiology of Aging*, Ahead of print, ISSN 0197-4580
- Vance C., et al. (2006). Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. *Brain*, Vol. 129, No. 4, (April 2006), pp. 868-876, ISSN 0006-8950
- Vance C., et al. (2009). Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. *Science*, Vol. 323, No. 5918, (February 2009), pp. 1208-1211, ISSN 1095-9203
- Van Damme P., et al. (2011). Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. *Neurology*, Vol. 76, No. 24, (June 2011), pp. 2066-2072, ISSN 0028-3878
- Van Deerlin VM., et al. (2008). TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. *Lancet Neurology*, Vol. 7, No. 5, (May 2008), pp. 409-416, ISSN 1474-4422
- Van Deerlin VM., et al. (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nature Genetics*, Vol. 42, No. 3, (March 2010), pp. 234-239, ISSN 1061-4036
- Van Es MA., et al. (2007). ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. *Lancet Neurology*, Vol. 6, No. 10, (October 2007), pp. 869-877, ISSN 1474-4422
- Van Es MA., et al. (2008). Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. *Nature Genetics*, Vol. 40, No. 1, (January 2008), pp. 29-31, ISSN 1061-4036
- Van Es MA., et al. (2009). A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. *Neurology*, Vol. 72, No. 3, (January 2009), pp. 287-288, ISSN 0028-3878
- Van Es MA., et al. (2009). Analysis of FGGY as a risk factor for sporadic amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*, Vol. 10, No. 5-6, (October-December 2009), pp 441-447, ISSN 1748-2968
- Van Es MA., et al. (2009). Genome-wide association study identifies 19p13.11 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. *Nature Genetics*, Vol. 41, No. 10 (October 2009), pp. 1083-1087, ISSN 1061-4036
- Van Es MA., et al. (2011). Angiogenin variants in Parkinson's disease and amyotrophic lateral sclerosis. *Annals of Neurology*, 2011: Ahead of print
- Van Vught PW., et al. (2005). Lack of association between VEGF polymorphisms and ALS in a Dutch population. *Neurology*, Vol. 65, No. 10, (November 2005), pp. 1643-1645, ISSN 0028-3878

- Vantaggiato C., et al. (2011). Senataxin modulates neurite growth through fibroblast growth factor 8 signalling. *Brain*, Vol. 134, Pt. 6, (June 2011), pp. 1808-1828, ISSN 0006-8950
- Varoqueaux F., et al. (2002). Total arrest of spontaneous and evoked synaptic transmission but normal synaptogenesis in the absence of Munc13-mediated vesicle priming. *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 99, No. 13, (June 2002), pp. 9037-9042, ISSN 0027-8424
- Varoqueaux F., et al. (2005). Aberrant morphology and residual transmitter release at the Munc13-deficient mouse neuromuscular synapse. *Molecular and Cellular Biology*, Vol. 25, No. 14, (July 2005), pp. 5973-5984, ISSN 0270-7306
- Veldink JH., et al. (2001). Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. *Neurology*, Vol. 56, No. 6, (March 2001), pp. 749-752, ISSN 0028-3878
- Veldink JH., et al. (2005). SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. *Neurology*, Vol. 65, No. 6, (September 2005), pp. 820-825, ISSN 0028-3878
- Vilariño-Güell C., et al. (2009). Characterization of DCTN1 genetic variability in neurodegeneration. *Neurology*, Vol. 72, No. 23, (June 2009), pp. 2024-2028, ISSN 0028-3878
- Wang XS., et al. (2004). Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. *Journal of the Neurological Sciences*, Vol. 227, No. 1 (December 2004), pp. 27-33, ISSN 0022-510X
- Wang Y., et al. (2007). Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. *Journal of Neuroscience*, Vol. 27, No. 2, (January 2007), pp. 304-307, ISSN 0270-6474
- Wang J, Campbell IL & Zhang H. (2007). Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system. *Molecular Psychiatry*, Vol. 13, No. 3, (March 2008), pp. 293-301, ISSN 1359-4184
- Watts GD., et al. (2004). Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nature Genetics*, Vol. 36, No. 4, (April 2004), pp. 377-381, ISSN 1061-4036
- Wehl CC., et al. (2008). TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, Vol. 79, No. 10, (October 2008), pp. 1186-1189, ISSN 0022-3050
- Williamson TL., et al. (1998). Absence of neurofilaments reduce the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. *Proceedings of the National Academy of Sciences of the USA*, Vol. 95, No. 16, (August 1998), pp. 9631-9636, ISSN 0027-8424
- Wills AM., et al. (2009). A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS. *Neurology*, Vol. 73, No. 1, (July 2009), pp. 16-24, ISSN 0028-3878
- Wu D., et al. (2007). Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. *Annals of Neurology*, Vol. 62, No. 6, (December 2007), pp. 609-617, ISSN 0364-5134
- Xiao S., et al. (2008). An aggregate-inducing peripherin isoform generated through intron retention is upregulated in amyotrophic lateral sclerosis and associated with

- disease pathology. *Journal of Neuroscience*, Vol. 28, No. 8, (February 2008), pp. 1833-1840, ISSN 0270-6474
- Yamasaki S., et al. (2009). Angiogenin cleaves tRNA and promotes stress-induced translational repression. *Journal of Cell Biology*, Vol. 185, No. 1, (April 2009), pp. 35-42, ISSN 0021-9525
- Yan J., et al. (2006). A major novel locus for ALS/FTD on chromosome 9p21 and its pathological correlates. *Neurology*, Vol. 67, No. 1, (July 2006), pp. 186-186b, ISSN 0028-3878
- Yan J., et al. (2010). Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. *Neurology*, Vol. 75, No. 9, (August 2010), pp. 807-814, ISSN 0028-3878
- Yang Y., et al. (2001). The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. *Nature Genetics*, Vol. 29, No. 2, (October 2001), pp. 160-165, ISSN 1061-4036
- Yen AA., et al. (2004). HFE mutations are not strongly associated with sporadic ALS. *Neurology*, Vol. 62, No. 9, (May 2004), pp. 1611-1612, ISSN 0028-3878
- Zawiślak D., et al. (2010). The -A162G polymorphism of the PON1 gene and the risk of sporadic amyotrophic lateral sclerosis. *Neurologia I Neurochirurgia Polska*, Vol. 44, No. 3, (May 2010), pp. 246-250, ISSN 0028-3843 (Abstract)
- Zhang Y., et al. (2006). VEGF C2578A polymorphism does not contribute to amyotrophic lateral sclerosis susceptibility in sporadic Chinese patients. *Amyotrophic Lateral Sclerosis*, Vol. 7, No. 2, (June 2006), pp. 119-122, ISSN 1748-2968
- Zhang Y., et al. (2007). Loss of Vac14, a regulator of the signaling lipid phosphatidylinositol 3,5-biphosphate, results in neurodegeneration in mice. *Proceedings of the National Academy of Sciences of the USA*, Vol. 104, No. 44, (October 2007), pp. 17518-17523, ISSN 0027-8424
- Zhao ZH., et al. (2009). A novel mutation in the senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis*, Vol. 10, No. 2, (April 2009), pp. 118-122, ISSN 1748-2968



## **Amyotrophic Lateral Sclerosis**

Edited by Prof. Martin Maurer

ISBN 978-953-307-806-9

Hard cover, 718 pages

**Publisher** InTech

**Published online** 20, January, 2012

**Published in print edition** January, 2012

Though considerable amount of research, both pre-clinical and clinical, has been conducted during recent years, Amyotrophic Lateral Sclerosis (ALS) remains one of the mysterious diseases of the 21st century. Great efforts have been made to develop pathophysiological models and to clarify the underlying pathology, and with novel instruments in genetics and transgenic techniques, the aim for finding a durable cure comes into scope. On the other hand, most pharmacological trials failed to show a benefit for ALS patients. In this book, the reader will find a compilation of state-of-the-art reviews about the etiology, epidemiology, and pathophysiology of ALS, the molecular basis of disease progression and clinical manifestations, the genetics familial ALS, as well as novel diagnostic criteria in the field of electrophysiology. An overview over all relevant pharmacological trials in ALS patients is also included, while the book concludes with a discussion on current advances and future trends in ALS research.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Max Koppers, Michael van Es, Leonard H. van den Berg, Jan H. Veldink and R. Jeroen Pasterkamp (2012). Genetics of Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis, Prof. Martin Maurer (Ed.), ISBN: 978-953-307-806-9, InTech, Available from: <http://www.intechopen.com/books/amyotrophic-lateral-sclerosis/genetics-of-als>

**INTECH**  
open science | open minds

### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.